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 A library of furanosteroids was synthesized by oxidation of a catechol and a 4-
hydroxycoumarin with potassium ferricyanide. Further diversification of these substrates was 
achieved through various acetalization reactions. The resultant compounds were then evaluated 
as potential inhibitors against PI3-kinase using a competitive ELISA assay. As an extension to 
this initial library, a subset of cromolyn derivatives were synthesized and subsequent biological 
evaluation of these compounds is underway. Secondly, studies have been ongoing to achieve the 
total synthesis of pleurotin featuring an in situ hydrozirconation-transmetallation-aldehyde 
addition process followed by an Ireland-Claisen rearrangement and finally an intramolecular 
Diels-Alder cyclization. Previous difficulty with the installation of the C8-C9-C21 side-chain and 
the configuration at the C10 center led us to pursue the 9-normethylpleurotin analog. In our 
efforts to address this stereochemistry issue difficulties arose in scaling up the initial route to our 
key starting aldehyde for the hydrozirconation-transmetallation-aldehyde addition. Therefore an 
alternative route was developed utilizing a benzyne-furan [4 + 2]-cycloaddition.  
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1.0  SYNTHESIS AND BIOLOGICAL EVALUATION OF FURANOSTEROID 
LIBRARY AS PI3-KINASE INHIBITORS 
1.1 INTRODUCTION 
Phosphatidylinositol 3-kinases (PI3Ks) are members of a widely expressed enzyme family that 
catalyzes phosphorylation at the 3-position of the inositol ring in phosphoinositides (Figure 1).1 
The PI3K enzyme is found in cellular complexes containing ligand activated growth factor 
receptor and oncogene protein tyrosine kinases.2 The PI3Ks are involved in the regulation of 
diverse cellular processes that are essential for cell growth and differentiation, including cell 
proliferation, cell survival, cytoskeletal organization, vesicle trafficking, glucose transport, and 
platelet function.3 It has been shown that PI3K activity is elevated in response to platelet-derived 
growth factor (PDFG), insulin, insulin-like growth factor 1 (IGF-1), colony stimulating growth 
factor 1 (CSF-1), nerve growth factor (NGF), hepatocyte growth factor (HGF), stem cell growth 
factor, and epidermal growth factor (EGF).2,4-6 The diverse range of PI3K functional effects are 
attributed to its activation by numerous receptors and the existence of multiple effector proteins 
that can interact with phosphatidylinositol (PtdIns) lipid products by different structural motifs.6 
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Figure 1. Structure of phosphatidylinositol (PtdIns) 
 
Table 1. PI3K Family Members  
Class Catalytic Subunit Adaptor/Binding Partner Distribution 
IA P110α p85α, p50α, p55α Broad 
 P110β p85β Broad 
 P110δ p55γ Leukocytes 
IB P110γ p101 Leukocytes 
II PI3K-C2 Clathrin Broad 
III PtdIns 3-Kinase p150 Broad 
 
The PI3Ks are divided into three classes based on structural homology and substrate 
specificity (Table 1).4,6 The most widely studied Class I enzymes are comprised of heterodimers 
and divided into two subclasses. Class Ia includes: three catalytic isoforms (p110α, p110β, 
p110δ) and five regulatory/adaptor isoforms (p85α, p85β and p55γ encoded by specific genes 
and p55a and p50a that are produced by alternate splicing of p85α).6-9 Class Ib enzymes are 
comprised of a p110γ catalytic domain and a p101 adapter subunit and are expressed mainly in 
leukocytes.6,7 Four different lipid products are generated from Class I PI3Ks: the singly 
phosphorylated form PtdIns-3-P, the doubly phosphorylated forms PtdIns-3,4-P2 and PtdIns-3,5-
P2, and lastly, the triply phosphorylated form PtdIns-3,4,5-P3.10 The major products found within 
cells are PtdIns-3,4-P2 and PtdIns-3,4,5-P3 as they are transiently induced upon cell stimulation.6 
Both PtdIns-3,4-P2 and PtdIns-3,4,5-P3 selectively bind certain pleckstrin homology (PH) 
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domains, modular segments of 100 amino acids found in many signaling proteins.6 It has been 
suggested that the specificity of PI3K signaling is due to the ability of PH domains to 
differentiate between the various PtdIns lipid products, as they are able to trigger and propagate 
downstream signaling events.6 Class II PI3Ks are monomeric enzymes and are characterized by 
the presence of a C2 domain at the carboxyl-terminus.6,9 They consist of broadly expressed 
PI3K-C2α and PI3K-C2β isoforms as well as the liver specific PI3K-C2γ isoform.9 Class III 
PI3Ks are heterodimeric enzymes that consist of a p150 adaptor subunit and a PI3-Kinase 
producing catalytic subunit.9 
Activation of the PI3K pathway is a feature common to a variety of human cancers. Both 
PI3K gene amplification and protein overexpression have been found in lung, breast, and ovarian 
cancer cells.11,12 Activating mutations in the catalytic subunit of PI3K (p110α) have been found 
in breast, colorectal, and brain tumors.12-16 The PI3K pathway is downregulated by the tumor 
suppressor protein phosphatase and tensin homoglogue (PTEN). Consequently, if a mutation or a 
deletion to PTEN occurs it leads to increased tumor growth, which has been seen in a striking 
number of human tumors.17 The elucidation of downstream signaling events was largely 
achieved through the use of small molecule inhibitors such as wortmannin (Figure 2).18 Studies 
have shown that wortmannin competes with ATP for binding to the PI3K catalytic domain 
irreversibly via a covalent interaction of a critical lysine residue.18-20   
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Figure 2. General scaffold for viridin class of natural products 
 
Wortmannin (2) is a member of the viridin family of natural products that is comprised of 
several pentacyclic furanosteroids isolated as fungal metabolites from species such as 
Gliocladium virens, Gliocladium deliquescen, and Penicillium wortmanni (Figure 2).21,22 These 
furanosteroids not only possess antibiotic and antifungal properties, but they also inhibit various 
stages of cell signaling processes.23 Members of the viridin class, such as viridin (1) and 
wortmannin (2) are characterized by their unusual steroid structure possessing a furan fused 
between the A and B rings, as well as an aromatic C-ring.21 A key feature of this unique 
pentacyclic scaffold is the presence of two carbonyl groups flanking the furan moiety, which 
have been suggested to enhance the electrophilic nature of the ring system, contributing to its 
reactivity in biological systems.22  
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Figure 3. Proposed mechanism of action of PI3K inhibition by wortmannin  
 
Wortmannin was first reported to be a potent anti-inflammatory agent, however later it 
was discovered to be a potent irreversible and selective inhibitor of PI3-kinase (IC50= 4.2 
nM).19,20,22 The mechanism in which PI3K is suggested to interact with wortmannin involves 
attack of Lys802 of the catalytic site of p110α18 and Lys883 of p110δ on the electrophilic C20 
carbon (Figure 3).18,24 The Lys802 residue is found in the ATP-binding site of the p110 catalytic 
domain and therefore plays a critical role in the phosphotransfer reaction. Various structure 
activity relationship studies by Norman and co-workers support the susceptibility of nucleophilic 
attack at this C-20 position of wortmannin by both primary and secondary amines.19,25,26  
In 2004, Wipf and co-workers synthesized a library of 94 synthetic viridins and a series 
of 5 C-20 thioether derivatives through the nucleophilic ring opening of Wortmannin at the C-20 
position.2 Each sample was screened for its ability to inhibit PI3-kinase and mTOR in a variety 
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of tumor cell lines by the Powis group and the National Cancer Institute. Among these initial 
compounds, ten of the most potent candidates were selected for further investigation. Within the 
subset of ten, the bis-allyl derivative PX-866 produced the most promising biological results as a 
potent, specific, and irreversible inhibitor of PI3-kinase, demonstrating a lower liver toxicity and 
greater promise for inhibition of cell growth over the lead structure wortmannin (Figure 4).2   
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Figure 4. Synthetic viridins obtained via nucleophilic ring opening of wortmannin and the structure 
of PX-866 
Since this discovery, PX-866 has been shown to be a biologically stable inhibitor of PI3-
kinase in vitro and in vivo.7,12,27 PX-866 has demonstrated oral efficacy and PI3K inhibition in 
numerous human xenografts models in mice.7,12,27 It has also been shown that PX-866 enhances 
the antitumor activity of other chemotherapeutic drugs and radiation.7,12 Most recently, in 2008, 
PX-866 entered phase I clinical trials and is being developed clinically as an oral formulation for 
patients with advanced solid metastatic tumors.  
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1.2 LIBRARY SYNTHESIS AND SCAFFOLD DIVERSIFICATION 
Our interdisciplinary drug discovery program utilizes novel natural product scaffolds as the 
foundation of diversity oriented library synthesis.2,28,29 The viridin class of compounds has been 
used as a benchmark for the development of selective kinase inhibitors. Our specific objectives 
for this library synthesis were to develop synthetic analogs containing the fused electrophilic 
benzofuran core similar to that found in wortmannin.  
Recently, syntheses of related furanosteroids, the coumestans, have been reported using a 
variety of methods such as electrochemical oxidations,30-32 Pd and Ag mediated cyclizations,33-36 
photochemical processes,37 as well as enzymatic methods with tyrosinase38 and laccase, a 
multicopper oxidase that are capable of oxidizing a variety of substrates while concomitantly 
reducing O2.39  
OH
OH
R
O
O
RPhI(OAc)2, MeOH, rt
90 -99%
R= alkyl  
Figure 5. Oxidation of 1,2-dihydroxybenzenes with hypervalent iodine  
 
Recent interest in the use of hypervalent iodine reagents for the oxidation of quinols to 
quinones (Figure 5)40,41 led us to investigate their utility as reagents in our furanosteroid 
synthesis. We first screened a variety of hypervalent iodine reagents as oxidants in the 
intermolecular coupling of a 4-hydroxycoumarin and a catechol (Scheme 1). 
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Scheme 1. Reaction scheme for furanosteroid library synthesis 
 
Table 2. Oxidation conditions screened for intermolecular condensation reaction 
 
 
 
Entry Oxidant (equiv) Solvent Conc. (M) Time (h) Comment 
1 PIDA (2.0) MeOH 0.5 24 messy rxn mixture 
2 PIDA (1.0) CH3NO2 0.25 24 messy rxn mixture 
3 PIDA (1.0) CH3NO2 0.5 5b messy rxn mixture 
4 PIDA (1.0) CH3CN 0.5 3 messy rxn mixture 
5 PIDA (2.0) CH3CN 0.5 3 messy rxn mixture 
6 PIDA (2.0) CF3CH2OH 0.25 3 messy rxn mixture 
7 PIDA (2.0) CF3CH2OH 0.50 3 messy rxn mixture 
8 PIFA (1.2) CH3CN 0.50 3c no product observed 
9 PIFA (1.2) CF3CH2OH 0.10 3c no product observed 
10 PIFA (1.2) CF3CH2OH 0.10 24 no product observed 
11 PIFA (2.0) CF3CH2OH 0.10 3c no product observed 
12 NaIO3, py EtOH/H2O (9:1) 0.10 24 decomposition 
13 SIBX THF 0.05 24 decomposition 
14 DMP CH2Cl2 0.10 24 decomposition 
aall reactions were run at rt unless otherwise noted; breaction mixture was heated to 55 oC; creaction 
mixture was cooled to 0 oC. 
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Utilizing phenyliodonium diacetate (PIDA) in a variety of solvents and concentrations all 
led to messy reaction mixtures and no product formation was observed by 1H NMR analysis 
(Table 2, Entries 1-7). Testing the more electron rich phenyliodoium bis(trifluoroacetate) 
(PIFA) under a range of conditions also gave messy reaction mixtures and no product was 
observed by 1H NMR analysis (Table 2, Entries 8-11). Attempts to oxidize with sodium iodate 
and pyridine,42 stabilized 2-iodoxybenzoic acid (SIBX),43-45 or Dess Martin Periodinane (DMP) 
all resulted in decomposition with trace starting material observed by 1H NMR (Table 2, Entries 
12-15). 
Due to the lack of success with the hypervalent iodine reagents, we used a procedure 
developed by Wanzlick et al. using K3Fe(CN)6 as the oxidant for the intermolecular condensation 
of catechol with 4-hydroxycoumarin.46,47 In the 1960’s, Wanzlick reported the use of both 
K3Fe(CN)6 and NaIO3 reagents for the in situ generation of a quinone which then undergoes 
Michael addition of the present nucleophile to afford the respective coumarone products (Figure 
6).  
O
O
O
OH
OHOH
OHO O
OH
+
Na(OAc)2, NaIO3
1:1 Acetone/H2O
65%
O
O
OH
OH
+
O
O
OH
OH
K3Fe(CN)6, NaHCO3,
H2O, 58%
 
Figure 6. Wanzlick's synthesis of coumarone derivatives 
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The proposed mechanism for accessing these scaffolds, shown in Scheme 2, begins with 
the oxidation of catechol to the o-quinone. Michael addition of the nucleophile into the o-
quinone followed by aromatization generates the intermediate species 6. A second oxidation to 
the o-quinone allows for ring closure to form the 5-membered ring and aromatization gives the 
desired furanosteroid.  
OH
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O
O
R
-2 e- -2H+
O
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+
R
O O
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O
R
OH
O
O
OH
HO
R
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HO
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R
O
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O
O
+ H+
R
O
O
O
O
OH
aromatize
R
O
O
O
OH
OH
+ H+
6
 
Scheme 2. Mechanism for the intermolecular cyclization reaction 
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For our synthesis, a solution of catechol (4), 4-hydroxycoumarin (3), and NaOAc in 
water/THF was treated with K3Fe(CN)6 to provide the resultant furanosteroid 5 (JLV1001) in 
35% yield (Scheme 3). Using this K3Fe(CN)6 protocol, five additional library members were 
synthesized from a selection of commercially available catechols and 4-hydroxycoumarins 
(Scheme 4).30,32  
O
O
O
OH
OH
OH
OHO O
OH
+
K3Fe(CN)6, NaOAc
H2O/THF, 35%
3 4 5  
Scheme 3. Intermolecular condensation using K3Fe(CN)6 
 
O
O
O
R1
OH
OH
R2
OH
OH
R2
O O
OH
+
K3Fe(CN)6, NaOAc
 
THF:H2O, 1:1
R1
JLV1009 (7) R1= H, R2= OMe; 31%
JLV1052 (8) R1= H, R2= Me; 18%
JLV1055 (9) R1= Me, R2= H; 25%
JLV1061 (10) R1= Me, R2= Me; 30%
JLV1066 (11) R1= Me, R2= OMe; 15%  
Scheme 4. Synthesis under potassium ferricyanide conditions 
 
The products were isolated via filtration or extraction and purified via recrystallization. In 
all cases, the product was obtained as a single regioisomer and the structures were confirmed by 
HMBC 2-D NMR experiments (Figure 7). 
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Figure 7. Relevant HMBC correlations for synthetic analogs 
 
According to the HMBC spectral data for entry JLV1052 (8), the H-13 methyl protons 
correlated to the hydroxyl containing carbons, C-9 and C-8, as well as furan carbon C-10a but 
not the C-11a furan carbon. The H-7 proton showed cross peaks with both of the hydroxyl 
containing carbons C-9 and C-8, as expected. A correlation between H-7 and C-10a was apparent 
as well as a correlation between H-7 and the C-11a carbon of the furan ring.  These are 
consistent with the proposed structure for JLV1052 (8).  The structures for JLV1009 (7), 
JLV1061 (10), and JLV1066 (11) were determined in an analogous fashion where the H-7 
proton showed a correlation with the C-11a quaternary carbon at the furan ring junction. In 
support of these analyses, the 1H and 13C NMR data for analog JLV1066 (11) were an exact 
match for the known compound.39  
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Two additional library members were accessed using Wanzlick’s literature protocol46,47 
in which dimedone (12) and catechol (4) were treated with NaHCO3 and K3Fe(CN)6 in water, 
generating the requisite benzofuran 13 (JLV1081) in 42% yield (Scheme 5). The catechol 
moiety of the benzofuran was subsequently converted to the formylidene acetal with CH2BrCl 
and Cs2CO3 to give 14 (JLV1086) in 24% yield. 
O
O
OH
OH
+
O
O
OH
OH
K3Fe(CN)6, 
NaHCO3, H2O
CH2BrCl, Cs2CO3,
DMF, Reflux
O
O
O
O
42%
24%
JLV1081
JLV1086
12 4 13
14
 
Scheme 5. Condensation reaction and subsequent formylidene formation 
 
Side chain diversification in this series was achieved via the acetalization of the catechol 
moiety as the 2-ethylidene ester (Scheme 6). Compounds 5 (JLV1001) and 13 (JLV1081) were 
treated with methylpropynoate (15) and DMAP in CH3CN to afford compounds 16 (JLV1113) 
and 17 (JLV1103) in 21% and 43% yield, respectively.48  
 14 
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O
O
O
O
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O
O
O
43%
21%
JLV1113
JLV1103
5
13
15
16
17  
Scheme 6. Acetalization of catechol moiety of compounds 5 and 13 
 
Additionally, we found that we could enhance structural complexity via an E-ring 
annulation of 9 (JLV1055) with DMAD and t-butyl isocyanide (18).49,50 This process gave rise 
to one of two potential regioisomers depicted in Scheme 7. Analysis of the HMQC and HMBC 
spectra (Figure 8) showed that the three relevant protons (shown in green) had a 4-bond 
correlation with a common carbon, C6a. Compound 19 has one of the relevant protons is four 
bonds away from the common carbon; however, the other two relevant protons are three bonds 
and five bonds away from the C6a carbon (shown with blue arrows). In compound 20, the three 
differentiating protons (shown in green) have a 4-bond correlation with one common carbon, C6a. 
Thus, the HMBC data supports the structure for regioisomer 20. Initially, we thought that 
compound 19 would be the major product due to how sterically crowded compound 20 seems to 
be between the methylester and the lactone carbonyl. Perhaps due to the rigid planar nature of 
this steroid-type system those interactions do not hamper the formation of this compound as the 
exclusive product.   
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Scheme 7. Potential products from E-ring annulation via a multicomponent reaction manifold 
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1.3 BIOLOGICAL RESULTS FOR PI3-KINASE INHIBITORS 
A library totaling 18 compounds comprised of 11 synthetic furanosteroid analogs (Figure 9) and 
7 commercially available compounds purchased from Sigma-Aldrich, Acros, and TIM-TEC 
(Figure 10) was submitted to Dr. Garth Powis, the director of the Center for Targeted Therapy at 
the University of Texas M. D. Anderson Cancer Center and tested as inhibitors against PI3-
kinase Ia p110 alpha.  
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Figure 9. Furanosteroid analogs tested for PI3K inhibition 
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Figure 10. Commercial compounds tested for PI3K inhibition 
 
The Powis group conducted a competitive assay with ATP against the active 
p110alpha/p85alpha PI3K using an ELISA colorimetric assay. Essentially, PtdIns-P2, ATP, the 
active enzyme and the compound of interest were added to a buffered solution and the 
conversion of PtdIns-P2 to PtdIns-P3 was measured. The control for this assay was wortmannin, 
which was evaluated at 1 nM and 10 nM final concentrations in DMSO.  
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An initial diagnostic screen of the compounds against PI3-K p110 alpha was conducted 
and the results are summarized in Table 3. Compounds JLV1009 (7), JLV1052 (8), JLV1081 
(13), JLV1103 (17), JLV1113 (16), JLV1123 (20), JLV1156 (22), and JLV1157 (23) were not 
active, all possessing IC50 values greater than 1 µM. The IC50 for compounds JLV1001 (5), 
JLV1055 (9), JLV1061 (10), JLV1066 (11), JLV1086 (14), and JLV1155 (21) were in the 0.01 
µM range. 
 
Table 3. Biological results against PI3K 
Compound Compound ID 
PI3-K p110 alpha  
IC50 (µM) 
5 JLV1001 ≥ 1.0  
7 JLV1009 < 1.0  
8 JLV1052 < 1.0  
9 JLV1055 > 0.01 
10 JLV1061 > 0.01  
11 JLV1066 ≥ 0.01 
13 JLV1081 < 1.0  
14 JLV1086 ≥ 0.01  
16 JLV1113 < 1.0  
17 JLV1103 < 1.0  
20 JLV1123 < 1.0  
21 JLV1155 ≥ 0.01  
22 JLV1156 < 1.0  
23 JLV1157 < 1.0  
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 The compounds were initially assayed against the active enzyme p110 alpha in two 
batches and their percent inhibition was measured at 0.0001, 0.001, 0.01, 0.1, and 1 µM (Figure 
11). In the first batch, compounds JLV1009 (7), JLV1052 (8), JLV1081 (13) were the least 
potent inhibitors, producing no more than a 30% inhibition of enzyme activity at 0.01 µM. 
Compounds JLV1055 (9) and JLV1001 (5) were more potent causing a decrease in enzyme 
activity within the 48-55% range at 0.01 µM. The most promising compound for this first batch 
was JLV1061 (10), which reduced the activity of the enzyme to 43% at 0.01 µM. 
  
 
Figure 11. JLV compound activity against p110 alpha  (batch 1) 
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In the second batch, none of the compounds inhibited the enzyme below 60% at 0.001 
µM (Figure 12). Compounds JLV1155 (21) and JLV1156 (22) were the best inhibitors at 0.01 
µM, where both reduced activity to 52% and 55%, respectively. At 1 µM, JLV1086 (14) and 
JLV1155 (21) reduced the enzyme activity to 47% and 45%, respectively.  
 
 
Figure 12. JLV compound activity against p110 alpha (batch 2) 
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The compounds exhibiting moderately potent IC50 values determined by the initial 
diagnostic screen were analyzed further in a second series of assays against p110 alpha and p110 
delta.  In the assay against p110 alpha the compounds were evaluated at 0.01, 0.1 and 1.0 µM. 
All of the compounds inhibited the active enzyme only to about 50% activity with the exception 
of JLV1155 (21), which demonstrated about 75% inhibition of the active enzyme (Figure 13). 
Interestingly, JLV2010 (27) showed promising inhibitory effects at 1 µM, producing a decrease 
in enzyme activity to below 20%.   
 
 
Figure 13. JLV compound activity against p110 alpha 
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Compounds JLV1001 (5), JLV1155 (21), JLV2010 (27), and JLV1052 (8) were 
assayed against p110 delta and evaluated at 0.01, 0.1 and 1 µM (Figure 14). Compound 
JLV1155 (21) was the most potent inhibitor in this case with a percent inhibition of 75% at 0.1 
µM. Compound JLV1052 (8) exhibited a 40% inhibition of the active enzyme at 0.1 µM and 
compounds JLV2010 (27) and JLV1001 (5) showed a 20% inhibition or less.  
 
 
Figure 14. JLV compound activity against p110 delta 
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With compound JLV1155 (21) being the most promising hit from these assays we 
wanted to evaluate its inhibitory effects in tumor cells. Using the human lung adenocarcinoma 
epithelial cell line A549 and the breast cancer cell line MCF-7, JLV1155 (21) was tested at both 
1 µM and 10 µM and the effects were observed after 0, 16, and 24 h time points (Figure 15). For 
both cell lines, there was no inhibition observed even after 24 h.  
 
 
Figure 15. Biological results for JLV1155 (21) against A549 and MCF-7 cell lines 
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1.3.1 Conclusions and acknowledgements 
A library of furanosteriod derivatives was synthesized by an iron mediated condensation reaction 
of a catechol and a 4-hydroxycoumarin. The resultant furanosteroids were analyzed by 2D-NMR 
HMBC experiments to confirm the regiochemical outcome of the reactions. These compounds 
were diversified by acetalization of the catechol moiety and E-ring annulation via a 
multicomponent cyclization. These compounds along with 7 structurally related samples 
obtained from commercial sources were tested for their inhibitory activity against PI3K 
p110alpha/p85alpha. The compounds were analyzed via a competitive ELISA colorimetric 
assay. Each series of compounds were assayed at 0.01, 0.1, and 1.0 µM against the control, 
wortmannin in DMSO.  JLV1155 (21) was the most potent inhibitor against p110 alpha and 
p110 delta, with a 75% inhibition of both enzymes at 0.1 µM. With these promising results, we 
tested JLV1155 against A549 and MCF-7 tumor cell lines, both widely accepted as model cell 
lines for evaluating biological effects of potential inhibitors. Previous studies have shown that 
wortmannin is a potent inhibitor of PI3K in both cell types, thus making these cell lines suitable 
for preliminary biological assays.2,7 However, despite its potency in our competitive assay, when 
A549 and MCF-7 cancer cells were treated with this compound, there was no observed 
inhibitory effect. Based on the data from these assays there is no evidence that these compounds 
are binding to the ATP-binding site of the p110 domain of the active enzyme.  
We would like to thank Dr. Garth Powis and Nathan Ihle from the Center of Targeted 
Therapy for providing the biological assay data discussed in this chapter including graphs, 
charts, and figures.  
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1.4 CROMOLYN BASED INHIBITORS 
In our initial library of potential PI3-kinase inhibitors, the commercially available disodium 
cromoglycate (JLV2010, 27) exhibited an 85% inhibition of active enzyme PI3K-p110 alpha 
(Figure 13) and a 70% inhibition against PI3K-p110 delta at 1.0 µM (Figure 14). With these 
findings, we wanted to develop the SAR of this compound through the synthesis of several 
structural analogs.  
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Figure 16. Disodium cromoglycate (DSCG, 27) 
 
In the 1960’s, cromolyn or disodium cromoglycate  (DSCG) (Figure 16) was introduced 
as a clinical treatment for allergic diseases including asthma, rhinitis and conjunctivitis.51 The 
postulated mode of action of DSCG is related to its stabilizing effect on the mast cell membrane, 
preventing the release of the mediators of anaphylaxis, the exaggerated allergic reaction to a 
foreign protein resulting from previous exposure to the agent.52 Conventionally, anti-allergic 
activity has been measured by the ability of compounds to stabilize rat skin connective tissue 
mast cells (PCA test) or inhibit antigen-induced mediator release from passively sensitized 
human lung fragments.51,53 Since its discovery, however, researchers and clinicians now 
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recognize that asthma is a multicomponent disease and the therapeutic usefulness of DSCG is a 
result of more than one mode of action.51   
DSCG (27) is highly polar and has a low lipophilicity, which leads to its poor absorption 
in the gastrointestinal tract and rapid elimination from the body.51,52,54 As a result, DSCG is only 
an effective treatment for asthma if administered via inhalation. Although attempts to produce an 
orally effective anti-allergic agent have met with difficulty, recently the benefits of inhalation 
therapy have been recognized, and this method for administration is now widely preferred 
therapeutically for the treatment of asthma.51  
Although DSCG has been recognized as a leading treatment for allergic disease, to our 
knowledge this structural motif has not been studied as a potential inhibitor of the PI3-kinase 
pathway.  
 
1.4.1 Synthesis of cromolyn analogs 
The previously reported syntheses of cromolyn structural analogs have focused on derivatizing 
three major reactive sites: the carboxyl, hydroxyl, and keto functionalities (Figure 17).52 Studies 
have also been conducted varying the type, length, and connectivity of the linker between the 
two chromene moieties (Figure 18).55  
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Figure 17. Three main sites of derivatization in cromolyn 
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Figure 18. Cromolyn derivatives with varying linker 
 
 
The focus of our synthesis of cromolyn analogs was to derivatize the parent structure in 
two areas: first by adding an additional substitution on the 2-hydroxypropane linker (R1) and 
secondly adding additional substitution on the chromene ring system (R2) (Figure 19). 
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Figure 19. General substitution pattern for cromolyn analogs 
 
For our synthesis of cromolyn analogs, 2’,6’-dihydroxyacetophenone 28 and 
epichlorohydrin (29) were heated at reflux in KOH and i-PrOH to give the bis-acetophenone (30) 
in 36% yield (Scheme 8). Treating compound 30 with diethyl oxalate (31) in sodium 
ethoxide/ethanol at reflux generated the desired bis-ester in 54% yield.54,55   
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Scheme 8. Synthesis of diethyl 5,5'-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-
carboxylate) 
 
Cromolyn derivatives could be synthesized using 2-substituted epichlorohydrin 
derivatives instead of commercially available epichlorohydrins. To that end, 2-methyl 
epichlorohydrin (34) was synthesized via epoxidation of 3-chloro-2-methylprop-1-ene (33) with 
m-CPBA in CH2Cl2 in 96% yield (Scheme 9).56      
 
Cl
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CH2Cl2, RT
96%
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33 34  
Scheme 9. Synthesis of 2-(chloromethyl)-2-methyloxirane (34) 
 
The resulting epichlorohydrin derivative 34 and 2’,6’-dihydroxyacetophenone (28) were 
treated with KOH in i-PrOH at reflux to generate bis-acetophenone 35 in 30% yield (Scheme 
10). Subsequent condensation with diethyl oxalate (31) in sodium ethoxide/ethanol at reflux 
generated the desired bis-ester 36 in 40% yield.  
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Scheme 10. Synthesis of diethyl 5,5'-(2-hydroxy-2-methylpropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-
chromene-2-carboxylate) (36). 
 
The synthesis of 2-(chloromethyl)-2-phenyloxirane (38) was achieved via the treatment 
of acid chloride 37 with chloroiodomethane and lithium bromide in THF (Scheme 11).57 Upon 
distillation of the crude reaction mixture, the desired epoxide 38 was obtained in 81% yield.  
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Scheme 11. Synthesis of 2-(chloromethyl)-2-phenyloxirane (37) 
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 Epoxide 38 and 2’,6’-dihydroxyacetophenone (28) were heated at reflux in KOH and i-
PrOH for 48 h to afford compound 39 in 21% yield (Scheme 12). Treatment of 39 with diethyl 
oxalate (31) in refluxing sodium ethoxide/ethanol generated the desired bis-ester 40 in low 4% 
yield, which can be attributed to mass loss during the difficult purification of the product from 
the reaction mixture. The 1H NMR for the crude ester 40 was significantly messier than that of 
the methyl analog 36. After an initial purification by column chromatography on silica gel, 
significant impurities were still present which made multiple purifications necessary.  
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Scheme 12. Synthesis of diethyl 5,5'-(2-hydroxy-2-phenylpropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-
chromene-2-carboxylate) (40) 
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In order to access different substitutions on the chromene core, 2,4,6-
trihydroxyacetophenone (41) was selectively protected as MOM-ether 43 via a two-step protocol 
(Scheme 13).58-60 Compound 41 was treated with DIPEA and MOMCl solution61 in CH2Cl2 to 
afford the 4,6-bis-MOM-ether 42 in 30% yield. Compound 42 was subsequently treated with 1% 
(w/v) I2 in MeOH to selectively deprotect the ortho-MOM ether function and furnish the mono-
MOM-ether 43 in 49% yield. 
 
OH O
OHHO
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    CH2Cl2, 0
 oC, 30%
OH O
OHMOMO
41 42
OH O
OMOMMOMO
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rt, 17 h, 49%
 
Scheme 13. Synthesis of 1-(2,6-dihydroxy-4-(methoxymethoxy)phenyl)ethanone  
 
Compound 43 was treated with KOH and epichlorohydrin (29) and heated at reflux in i-
PrOH for 48 h to give the desired bis-acetophenone 44 in 31% yield (Scheme 14). When 
compound 44 was treated with diethyl oxalate (31) in sodium ethoxide/ethanol at reflux, the 
desired bis-ester 45 was not observed. Analysis of the crude 1H NMR spectrum revealed that the 
MOM-ethers had been cleaved, perhaps during the acidic workup, and the product appeared to 
be a mixture of phenol containing compounds. The crude mixture did not contain the diagnostic 
α-proton of the α,β-unsaturated carbonyl group indicating that the condensation did not proceed. 
No further investigations to identify the compounds within this crude mixture were conducted. 
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Scheme 14. Synthetic approach toward diethyl 5,5'-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(7-
hydroxy-4-oxo-4H-chromene-2-carboxylate) (45) 
 
In the event that the condensation reaction with compound 44 had proceeded as expected 
our synthetic plans to further derivatize ester 45 are highlighted in Figure 20. We recognized 
that we could access a variety of analogs through the conversion of the free phenols to a variety 
of alkyl-ethers (ie. benzyl, MOM, or PMB) and esters (ie. acetyl). Additionally, the analogous 
bis-acids could be obtained via saponification of the ethyl ester providing another avenue for 
derivatization.   
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Figure 20. Synthetic plan for additional cromolyn derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
1.5 CONCLUSIONS 
In our initial biological investigations for PI3K inhibitors, compound JLV2010 (27, DSCG) was 
found to be the most potent at 1.0 µM concentration. A subset of analogs of 27 was synthesized 
via a two-step protocol. 2’6’-dihydroxyacetophenone was first dimerized with the 2-methyl and 
2-phenyl epichlorohydrin derivatives to form the requisite bis-phenol compounds. These 
substrates were subsequently condensed with diethyl oxalate to provide the desired bis-chromone 
compounds. Attempts to introduce additional substitution on the chromene ring were 
unsuccessful. Biological investigations of these derivatives as potential PI3-kinase inhibitors will 
be explored in future assays.   
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2.0  STUDIES TOWARD THE TOTAL SYNTHESIS OF PLEUROTIN 
2.1 INTRODUCTION 
Pleurotin (48), first isolated in 1947, is a fungal metabolite found in extracts of pleurota griseus, 
as well as Hohenbruehelia geogenius and Hohenbruhelia atrocaerulea (Figure 21). The 
structure was assigned by degradative studies62 in 1968, and later confirmed by x-ray 
crystallographic analysis.63 Structurally, pleurotin is an interesting synthetic target containing a 
hexacyclic core with 8 stereocenters, 6 of which are contiguous. Also present is a quinone 
moiety that contains two benzylic leaving groups critical for its reactivity in biological systems.  
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Figure 21. Structure of pleurotin
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2.1.1 Biology 
Preliminary biological investigations demonstrated that pleurotin (48) was significantly active 
against gram-positive bacteria, such as Staphylococcus aureus (0.8 µg/mL), Bacillus subtilis (0.2 
µg/mL), and Bacillus mycoides (1.6 µg/mL).64 Further studies reported potent antitumor activity 
against Erlich ascites carcinoma, L1210 lymphoid leukemia, and mammary tumors.64-66 Most 
interestingly, pleurotin has been identified as a potent inhibitor of the thioredoxin/thioredoxin 
reductase (Trx/TrxR) biological system.29   
2.1.1.1 Thioredoxin/Thioredoxin Reductase (Trx/TrxR)  
The thioredoxin reductases (TrxR) are low molecular weight flavoproteins that are 
widely expressed in prokaryotes and eukaryotes.67 The thioredoxins (Trx), belonging to a family 
of pyridine nucleotide-disulphide oxidoreductases, are homodimeric. Each monomer is 
composed of an FAD prosthetic group, an NADPH binding site, and a conserved redox-active 
disulfide containing amino acid active site (-Trp-Cys-Gly-Pro-Cys-Lys-).67-69 The reversible 
oxidation/reduction of the two cysteine (Cys) residues is essential for the biological activity of 
Trx. 69,70 Initially the Trx/TrxR system was studied in E. Coli71 with the conserved amino acid 
active site containing normal Cys residues.71 Later, it was discovered that the human thioredoxin 
active site differs from the bacterial Trx active site in that the Cys residues are replaced by 
selenocysteine (Sec) residues.67 The mammalian Trx/TrxR are expressed as isoforms localized in 
the cytosol (TrxR1, Trx1) and mitochondria (TrxR2, Trx2).67,72,73 TrxR1 is known for its potent 
and distinct immunomodulatory functions and TrxR2 is known for protecting against oxidative 
stress.67 The third isoform, TrxR3, is primarily expressed in the testis. In contrast to the other 
isoform, TrxR3 can reduce glutathione disulfide in addition to Trx, thus leading to the name, 
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TGR, for its thioredoxin/glutathione reductase activity.67,72,73 All three of the mammalian Trx 
isoforms are selenoproteins whose disulfide reduction activity involves a flexible active site 
located at the carboxy-terminus, making it easily accessible for both selective and irreversible 
modification by electrophiles. 
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Figure 22. Mechanism for Trx/TrxR system in E. Coli 
 
The mechanism of action for the Trx/TrxR system involves the transfer of electrons from 
NADPH by way of FAD to the active site disulfide of TrxR, which then goes on to reduce the 
substrate Trx (Figure 22).72 The Trx enzyme participates in various reductive cellular processes 
such as the reduction of Trx peroxidase for the conversion of hydrogen peroxide into water, as 
well as the conversion of ribonucleotides to deoxyribonucleotides for DNA synthesis.72 Trx also 
modulates transcription factor activities leading to increased binding to DNA and altered gene 
transcription. Studies have shown that Trx increases cell growth and also inhibits apoptosis.72,74 
TrxR1 is essential for maintaining redox homeostasis and protecting against oxidative damage 
and mutation in normal cells, however upon transformation into malignant cells TrxR1 supports 
tumor growth and progression.75 In general, Trx protein levels are elevated in several human 
primary cancers with significant correlations between increased Trx levels, tumor proliferation, 
and inhibited apoptosis. 29,74,76  
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The diverse range of biological functions of TrxR1 involved in the development and 
progression of cancer suggests that inhibiting Trx/TrxR is an ideal target for antitumor therapies. 
The objective of Trx targeting often involves the potential conversion from an antioxidant into a 
pro-oxidant Trx species in vitro and in vivo.75 Many tumor cells possessing increased TrxR 
levels also display a significant resistance to chemotherapy, thus inhibition of Trx could aid in 
preventing or reversing resistance mechanisms.75 Evidence has also shown that TrxR expression 
correlates with apoptotic resistance in various cancers.69,74,77    
A selection of known Trx/TrxR inhibitors, highlighted in Figure 23, demonstrate the 
structural diversity among the various known agents for the inhibition of Trx/TrxR. The 
nitrosoureas, such as bis-chloroethyl-nitrosurea (BCNU) 49, are non-selective alkylating agents 
that inhibit NADPH-reduced TrxR and GR.75 Their ability to cross the blood-brain barrier makes 
them promising treatments against malignant gliomas, such as glioblastoma. Both Au and Pt-
phospholes 50 have been developed as potent antiglioma agents via inhibition of TrxR in vitro.75 
The curcumin flavinoids 51, representing naturally occurring polyphenol compounds, have been 
identified as efficient and oxidative stress-inducing inhibitors of mammalian TrxR in vitro with 
potential antitumor activity in various human cancer cell lines.75,78 Auranofin 52, a gold (I) 
thiosugar known for its activity against lymphocyte leukemia P338,79 has been found to induce 
production of mitochondrial hydrogen peroxide at submicromolar concentrations related to TrxR 
inhibition.75,80-82 Earlier this year, the related gold (I) phosphine complex 53, containing a 
naphthalimide ligand, exhibited significant antiproliferative effects and induction of apoptosis 
via mitochondrial pathways, suggesting that it could be a key candidate for TrxR inhibition.82 
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Figure 23. Known Trx/TrxR inhibitors 
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In 2004, Wipf and co-workers determined that palmarumycin CP1 (54) is a potent 
inhibitor of TrxR-1/TrxR (IC50 = 0.35 µM), MDA-MB-231 (IC50 = 2.4 µM) and MCF-7 (IC50 = 
1.0 µM) in vitro (Figure 23).29,75,83 Based on these findings, a library of palmarumycin CP1 (54) 
analogs was developed demonstrating comparable inhibitory activity against Trx/TrxR to that of 
pleurotin (48) (IC50 = 0.17 µM).83,84 In the late 1990’s, 2-imidazoyl disulfides were identified as 
inhibitors of Trx/TrxR.85 More specifically, PX-12 (55) was identified as an irreversible inhibitor 
of Trx-1. PX-12 inhibits expression of VEGF in both cells and human xenografts by preventing 
stimulation of transcription factor HIF-1 by Trx-1.86 In 2004, PX-12 was the first Trx/TrxR 
inhibitor to enter into phase I clinical trials and studies are on going for its development as a drug 
candidate.87,88 AW464 (56) is a novel benzothiazole substituted quinol compound that is active 
against colon (HCT116 and HT29), renal (CAKI-1 and ACHN), and certain breast cancer cell 
lines (MCF7, MDA-N, and MDA-MB435).89 
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2.1.2 Previous Synthetic Efforts of Pleurotin 
2.1.2.1 Hart’s racemic total synthesis 
Hart and co-workers published the first total synthesis of pleurotin (48) in 1988.66,90 This 
racemic synthesis featured a stereoselective free radical cyclization reaction that was previously 
developed in their research group (Figure 24). Their synthesis begins with amide 57, derived in 
two steps from benzoic acid, was treated with iodine in aqueous THF to form the iodo-lactone.  
Hydrolysis of the acetal with formic acid to generate the requisite aldehyde and conversion to the 
α-β-unsaturated ester under Wittig conditions gave their radical cyclization precursor 58. Under 
radical conditions, 58 provided the desired tri-cycle 59 in 80% yield, the stereochemistry of 
which was confirmed by x-ray analysis.66 Several functional group manipulations gave access to 
aldehyde 60, which under acidic conditions gave the crude acetal 61 as a mixture of 
diastereomers. Subjecting this mixture to BF3·OEt2 in toluene and several additional functional 
group manipulations afforded the desired pentacyclic dihydropleurotin acid (63) in 52% yield. 
This late stage intermediate was then subjected to a two-step oxidation protocol to generate 
racemic pleurotin (48) in 26 total steps, and 0.3% overall yield.66  
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Figure 24. Hart's racemic total synthesis  
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2.1.2.2 Kraus’ efforts toward the synthesis of pleurotin  
Synthetic efforts toward the pleurotin core by the Kraus group (Figure 25) published in 1990 
featured a tandem photo-enolization/Diels-Alder approach.91 Aldehyde 65, accessed in four steps 
from commercially available 2,5-dimethoxybenzylalcohol (64), was exposed to photo-
enolization conditions to initiate the radical cyclization. The subsequent thermal heating for a 
period of 40 h completed the tandem cyclization sequence and gave lactone 66 in 50% yield over 
the two steps. Silver oxide mediated oxidation generated quinone 67 in 28% yield.  
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H
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Figure 25. Kraus's approach to the pleurotin core  
 
Although the authors did not complete the synthesis of their target molecule, the 
construction of four rings of the hexacyclic pleurotin core in seven chemical manipulations was 
quite a remarkable accomplishment. Biological evaluation of this tetracyclic quinone showed 
comparable activity to pleurotin (48) against SR Leukemia and colon cancer cell lines.91   
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2.2 SYNTHETIC EFFORTS TOWARDS PLEUORTIN BY THE WIPF GROUP 
Initially, it was envisaged that 48 could be accessed via a late stage installation of the 7-
membered cyclic ether, which could arise from substrate 68 (Scheme 15). This late stage 
intermediate 68 could be synthesized via an intramolecular Diels-Alder reaction arising from 
aldehyde 70. This aldehyde could be generated via an Ireland Claisen rearrangement of ester 71, 
which ultimately could be accessed using our Zr-Zn transmetalation addition methodology92-96 of 
a suitably functionalized aldehyde (72) and a protected propargyl alcohol (73). 
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Scheme 15. First generation retrosynthesis for the total synthesis of pleurotin 
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Figure 26. Attempts to the epimerize C-10 center of pleurotin 
 
In our group’s previous efforts to synthesize the fungal metabolite, pleurotin, Dr. Sonia 
Rodriguez,97 Dr. Shinya Iimura,98 and Dr. Stephan Elzner99 faced many problems with the 
installation of the C8-C9-C21 side-chain and the stereochemistry at the C10 center. The tetracyclic 
core, obtained via a key intramolecular Diels-Alder reaction, afforded the incorrect 
stereochemistry at the C10 carbon (Figure 26A). Subsequent attempts to epimerize this center via 
oxidative conditions (Figure 26B) or alternatively introducing the C8-C9-C21 sidechain (Figure 
26C) proved to be unsuccessful.  Evaluation of these previous attempts to correct that 
stereocenter led to the need to modify our approach by pursuing the pleurotin analog that does 
not contain the problematic stereocenter at C-9 (Figure 27).  
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Figure 27. Structure of 9-normethylpleurotin
2.3 STUDIES TOWARD 9-NORMETHYL PLEUROTIN 
In an analogous route to what had been done previously in our labs, 9-normethylpleurotin 74 
could be accessed via a late stage ring closure of the cyclic ether, which could be obtained from 
aldehyde 75 (Scheme 16). The aldehyde stereochemistry would be set through a palladium-
mediated hydrogenation of naphthoquinone 76. Synthesis of this naphthoquinone could be 
achieved as described previously via a Zr-Zn transmetalation/addition followed by an Ireland-
Claisen rearrangement and Diels-Alder sequence.  
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Scheme 16. Retrosynthesis for 9-normethylpleurotin 
 
 
Aldehyde 79 (Scheme 17) was synthesized starting from commercially available 2’,5’-
dimethoxyacetophenone (81). The α-bromination of 81 was conducted via treatment with 
bromine in a 2:1 solution of diethylether and 1,4-dioxane in 68% yield. The resulting bromide 
was treated with potassium ethyl xanthate (83) in acetone to afford the requisite xanthate 84 in 
high yield. Compound 84 was then subjected to a two-step radical cyclization using Zard’s 
protocol100 with lauroyl peroxide (DLP) and vinyl pivalate (85) to give the desired tetralone 86 in 
38% yield. Next aromatization of 86 to the naphthol bromide (87) was achieved under oxidative 
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pyridine perbromide conditions, and then subsequent protection of the phenol as the MOM-ether 
proceeded smoothly to give bromide 88. Lastly, subjection of bromide 88 to a one-pot 
lithiation/formylation process afforded the desired aldehyde (79) in 81% yield.  
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Scheme 17. First generation aldehyde synthesis  
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In practice, the lithiation/formylation step often generated a significant quantity of the 
naphthol ether 89 (Scheme 18) as a byproduct, which was attributed to the presence of water 
entering the system, which quenches out the lithiated species prior to formylation.  We were able 
to sequester the formation of this side product by removing trace amounts of water from the 
DMF by filtration through neutral alumina immediately prior to its use. Additionally, we found 
that the naphthalene byproduct 89 obtained could be converted to the desired aldehyde 79 via a 
MOM-directed ortho-lithiation/formylation sequence.  
 
1.) t-BuLi, THF, -78 oC
2.) DMF -78 to RT
    61% (2 steps)
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Scheme 18. Alternate route to access aldehyde from naphthalene side product 
 
When this first generation approach was performed on large scale (ca. 100 g of 
acetophenone 81), problems arose due to the low yielding radical cyclization and the large 
quantity of resultant xanthate salts and peroxide by-products generated in the reaction resulting 
in a difficult purification. Partial removal of the xanthate salts was achieved using a repeated 
aqueous wash of the reaction mixture, however the greasy by-product resulting from the C12 
carbon chain of the lauroyl peroxide reagent was very difficult to remove by chromatography 
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and often required multiple purifications. Attempts to purify 86 by distillation led to 
decomposition. In light of these technical issues with the scale up of this synthesis, an alternative 
approach to access aldehyde 79 was developed.  
In the 1980’s, H. Hart and co-workers demonstrated that tetrabromo derivatives of 1,4-
disubstituted benzenes readily undergo a tandem benzyne-furan bis-annulation when treated with 
base in the presence of a furan to generate anthracenes (Figure 28).101-103    
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Figure 28. Anthracenes from tandem benzyne-furan bis-annulation of substituted benzenes  
 
Martin and co-workers utilized an intramolecular tandem benzyne-furan cycloaddition to 
construct the anthracene core of vineomycinone B2 (Figure 29).104 Their approach involved the 
construction of a benzyne precursor containing two furan silicon tethers on the substituted 
benzene ring. Cleavage of the tethers followed by ring opening/oxidation afforded suitably 
substituted anthracenes, which were then elaborated into their target natural product.  
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Figure 29. Martin's approach to anthracenes via a tandem benzyne-furan cycloaddition  
 
Recently, the Kozlowski group reported the synthesis of naphthalenes involving the in 
situ generation of a benzyne intermediate that undergoes a [4 + 2]-cycloaddition with 2-
methoxyfuran (Figure 30).105 The tandem ring-opening/methylation with Me2SO4 and K2CO3 in 
refluxing acetone afforded the highly functionalized naphthalene core of Purpuromycin 1 in good 
yield.   
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Figure 30. Accessing naphthalenes via a benzyne-furan cycloaddition  
 
In 1991, Suzuki and co-workers were able to access naphthalenes via the in situ 
generation of a benzyne intermediate followed by [4 + 2]-cycloaddition with various substituted 
furans.106 In their preliminary investigations, they explored differences in reactivity of various 
aryne precursors (Scheme 19). Three ortho-bromophenyl sulfonates 90 were treated with n-BuLi 
(1.2 equiv) in THF at -78 oC in the presence of benzofuran 91 (2.0 equiv) as a trapping agent to 
generate compound 92. The authors noted that both the mesylate and tosylate derivatives resulted 
in low yields despite the consumption of starting material. The triflate was the most promising 
starting material providing the desired product in 90% yield.  
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Scheme 19. Suzuki’s exploration of aryne reactivity in [4 + 2] cycloaddition  
 
Suzuki also investigated several halotriflates in this reaction manifold (Scheme 20), 
noting that switching the positions of the halide (-Y) and the leaving group (-OTf) had 
essentially no effect on the yield of the reaction. Comparing the efficiency of the iodide and 
bromide for benzyne generation it was observed that each was an equally suitable substrate for 
accessing the cycloadduct 99.  
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Scheme 20. Suzuki's evaluation of various halotriflates in [4 + 2] cycloaddition  
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In an extension of these investigations, α-alkoxyarynes were found to proceeded in an 
exclusive regioselective [4 + 2] cycloaddition with 2-methoxyfuran (101) through an analogous 
benzyne intermediate (Scheme 21).107 The three substrates when treated with n-BuLi in THF at -
78 oC and an excess of 2-methoxyfuran (101) afforded the desired cycloaddition to give 
intermediate 102, which upon aromatization provided the desired naphthols 103-105 in good 
yields.    
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Scheme 21. Accessing substituted naphthalenes via furan-benzyne [4 + 2] cycloaddition  
 
 
 
With benzyne having been used as a reactive intermediate to quickly access highly 
functionalized naphthalene derivatives we wished to apply this powerful methodology to the 
synthesis of our key aldehyde. We imagined that a suitable halotriflate would undergo a [4 + 2]-
cyclization with 2-methoxyfuran (101), which upon ring opening and methylation would afford 
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intermediate naphthalene 106 (Figure 31). Compound 106 could then be subjected to directed 
ortho-lithiation/formylation conditions to afford the desired aldehyde 79.  
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Figure 31. Utilizing a benzyne-furan cycloaddition for aldehyde synthesis 
 
In 2007, Suzuki published an organic synthesis protocol for the preparation of 
benzocyclobutanone derivatives via the efficient generation of benzynes (Figure 32). The 
protocol involved a scalable three-step synthesis of benzyne precursor 108 and showcased its 
utility in accessing benzocyclobutanones 110.  
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Figure 32. Suzuki's efficient synthesis of benzocyclobutanones 
Using this three-step protocol we synthesized both the MOM- protected and benzyl-
protected halotriflates to be tested in the initial cyclization sequence. The synthesis of 108 was 
realized in four steps from commercially available resorcinol 107 (Scheme 22).107 Treatment of 
107 with NaHCO3 and I2 in water generated the requisite 2-iodoresorcinol in 60% yield. 
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Subjecting 111 to DIPEA and Tf2O afforded the desired compound 112 in quantitative yield. 
Selective mono-deprotection of the bis-triflate 112 with Cs2CO3 and treatment with BnBr 
generated compound 108 in 57% over the two steps. Pre-mixing compound 108 and 2-
methoxyfuran (101) followed by dropwise addition of n-BuLi initiated the benzyne formation 
and immediately underwent the [4 + 2] cycloaddition. Subsequent ring opening and methylation 
of the free phenol afforded the desired naphthalene in 73% yield over the two steps. 
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Scheme 22. Synthesis of 5-(benzyloxy)-1,4-dimethoxynaphthalene  
 
Alternatively, 2-iodo-3-(methoxymethoxy)phenyl trifluoromethanesulfonate 114 could be 
synthesized via the mono-deprotection of 112 under Cs2CO3 conditions and subsequent 
protection as the MOM-ether (Scheme 23). However when MOM-ether 114 was subjected to the 
cycloaddition/ring opening and methylation sequence the desired product 89 was not observed.  
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Scheme 23. Attempt to synthesize 1,4-dimethoxy-5-(methoxymethoxy)naphthalene 
 
Thus, the synthesis of compound 89 was achieved by hydrogenolysis of benzyl-ether 113 
to afford 115 and subsequent protection as the MOM-ether provided substrate 89 in good yield 
(Scheme 24). As previously described the MOM-directed ortho-lithiation/formylation sequence 
provided aldehyde 79 in 60% yield.  
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Scheme 24. A second generation approach toward aldehyde 79 
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2.4 CONCLUSIONS 
In summary, a concise second-generation synthesis of aldehyde 79 was developed utilizing a 
benzyne-furan [4 + 2]-cycloaddition to access the naphthalene core. Using Suzuki’s organic 
synthesis protocol we were able to obtain the halo-triflate precursor in three steps from 
resorcinol. With this easily scalable substrate in hand, cycloaddition with 2-methoxyfuran 
proceeded nicely to generate the desired napthalene core. This alternative route to our key 
aldehyde not only decreased the length of the synthesis, but also eliminated the low yielding and 
problematic radical cyclization whose long reaction times, numerous byproducts, and difficult 
purifications hampered the efficient production of our key aldehyde. Studies are on going to 
elaborate this substrate for the synthesis of 9-normethylpleurotin (74).  
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3.0  EXPERIMENTAL 
3.1 GENERAL EXPERIMENTAL 
All moisture-sensitive reactions were performed under an atmosphere of nitrogen gas and all 
glassware was flame dried under high vacuum prior to use. Diethyl ether (Et2O) and 
tetrahydrofuran (THF) were dried via distillation from Na/benzophenone. Dichloromethane 
(CH2Cl2) and toluene were purified by filtering each solvent through activated alumina columns. 
Reactions were monitored by thin-layer chromatography (TLC) analysis using EM Science pre-
coated silica gel 60 F254 plates, 250 m layer thickness, and visualization was executed with a 
254 nm UV light and by staining with a p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2.0 
mL of acetic acid, and 3.5 mL of conc. sulfuric acid, in 100 mL of 95% ethanol). Flash column 
chromatography on SiO2 was used to purify crude reaction mixtures. Yields refer to 
chromatographically and spectroscopically (1H NMR) homogeneous materials unless otherwise 
stated.  
Melting points (Mp) are uncorrected and were determined using a Laboratory Devices 
Mel-Temp II apparatus. Infrared spectra (IR) were obtained using a Nicolet Avatar 360 FT-IR 
spectrometer or a Smiths Detection IdentifyIR FT-IR spectrometer. 1H and 13C NMR spectra 
were recorded on 300 MHz/75 MHz (1H/ 13C NMR), 500 MHz/125 MHz (1H/ 13C NMR), 600 
MHz/125 MHz (1H/ 13C NMR) using a Bruker Avance 300 MHz, a Bruker DRX 500 MHz, or a 
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Bruker DRX 600 MHz spectrometer with 5 mM cryoprobe in CDCl3 unless otherwise stated. 
Chemical shifts were reported in parts per million with the residual solvent peak used as an 
internal standard. 1H NMR spectra, recorded at 300 MHz, 500 MHz, or 600 MHz, were tabulated 
as follows: chemical shift (δ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad), number of protons, and coupling constant(s). 13C NMR spectra were 
recorded at 75 MHz/ 125 MHz using a proton-decoupled pulse sequence with a d1 of 10 sec and 
were tabulated by observed peak. Mass spectrometry (MS) data was collected using a Micromass 
Autospec double focusing instrument by the University of Pittsburgh’s Department of Chemistry 
Mass Spectrometry Facility.  
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3.2 LIBRARY EXPERIMENTAL 
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8,9-Dihydroxy-6H-benzofuro[3,2-c]chromen-6-on???5)??JLV1001).32,38,46,47,10?? ??????????
solution of NaOAc (6.0 g, 72.0 mmol), catechol (4.10 g, 36.0 mmol), and 4-hydroxycoumarin 
(5.92 g, 36.0 mmol) in 1:1 THF/H2O (360 mL) was treated with K3Fe(CN)6  (35.6 g, 108.0 
mmol) and stirred for 2 h. The precipitates formed were collected by vacuum filtration and 
recrystallized from 1:1 EtOH/Acetone to yield 3.40 g (12.7 mmol, 35%) of 5 as a tan solid 
powder: Mp 282 oC (dec.) (EtOH/Acetone); IR (neat) 3837, 3733, 3583, 3362, 3243, 2921, 2360, 
2339, 2050, 1700, 1624 cm -1; 1H NMR (300 MHz, DMSO-d6) δ 9.65 (s, 1 H), 9.53 (s, 1 H), 8.01 
(d, 1 H), 7.94 (d, 1 H, J = 6.9 Hz), 7.62 (t, 1 H, J = 8.1 Hz), 7.53 (t, 1 H, J = 7.2 Hz), 7.27 (s, 1 
H), 7.20 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 158.2, 157.9, 152.8, 149.9, 147.0, 145.2, 
131.7, 125.3, 121.6, 117.5, 114.3, 112.8, 106.0, 105.3, 99.4; MS (EI) m/z (rel intensity) 269 [M + 
1]+ (17), 268 [M]+ (100), 264 (14), 239 (15), 236 (21), 225 (5), 211 (6), 165 (5), 152 (6), 137 
(10), 123 (14), 109 (17), 97 (30), 83 (49), 81 (30), 70 (41), 68 (53), 66 (22), 55 (72); HRMS (EI) 
m/z calcd for C15H8O5 268.0372, found 268.0371. 
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8,9-Dihydroxy-10-methoxy-6H-benzofuro[3,2-c]chromen-6-one (7) (JLV1009).32 A 
solution of NaOAc (0.501 g, 6.0 mmol), 3-methoxycatechol (0.399 g, 3.0 mmol), 4-
hydroxycoumarin (0.487 g, 3.0 mmol) in 1:1 THF/H2O was treated with K3Fe(CN)6 (2.97 g, 9.0 
mmol) and stirred for 2 h. The precipitates formed were collected by vacuum filtration and the 
solid was recrystallized from 1:1 EtOH/Acetone to give 0.276 g (0.925 mmol, 31%) of 7 as an 
orange-red powder: Mp 222.2 – 223.7 oC (Acetone); IR (neat) 3738, 3583, 3305, 3270, 2923, 
1731, 1616, 1466, 1373, 1092, 1021 cm -1; 1H NMR (500 MHz, DMSO-d6) δ 9.66 (s br, 1 H), 
9.14 (s br, 1 H), 8.06 (dd, 1 H, J = 8.0, 1.5 Hz), 7.66 (td, 1 H, J = 7.0, 1.5 Hz), 7.57 (d, 1 H, J = 
8.0 Hz), 7.47 (t, 1 H, J = 8.0 Hz), 7.06 (s, 1 H), 4.08 (s, 1 H); 13C NMR (125 MHz, DMSO-d6) 
δ 158.0 and 157.5 (C-6 or C-11b), 152.4 (C-12), 145.9 (C-8), 141.7 (C-10a), 138.1 (C-9), 133.6 
(C-10), 131.5 (C-1), 124.9 (C-4), 121.3 (C-3), 117.1 (C-2), 114.2 and 112.3 (C-4a or C-6a), 
105.5 (C-11a), 99.3 (C-7), 60.6 (C-13); observed correlations in HMBC spectrum (H to C): C-1 
(H-1, H-2 or H-3), C-2 (H-2, H-3), C-3 (H-2, H-3), C-4 (H-2 or H-3, H-4), C-4a (H-1, H-2), C6 
(H-1, H-4), C-6a (H-2, H-3, H-7), C-7 (H-7), C-8 (H-7, H-8, H-9), C-9 (H-7, H-8, H-9), C-10 
(H-7, H-9, H-13), C-10a (H-7), C-11a (H-7), C-11b (H-1, H-4), C-12 (H-1, H-2, H-3, H-4), C-13 
(H-13); MS (EI) m/z (rel intensity) 298 [M]+ (23), 287 (25), 286 (100), 283 (14), 200 (28), 194 
(20), 180 (12), 165 (17), 133 (24), 117 (89), 115 (34), 105 (18), 91 (40), 89 (62), 81 (27), 69 
(42), 57 (75); HRMS (EI) m/z calcd for C16H10O6 298.0477, found 298.0461.  
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8,9-Dihydroxy-10-methyl-6H-benzofuro[3,2-c]chromen-6-one (8) (JLV1052).32 A 
solution of NaOAc (0.332 g, 4.00 mmol), 3-methylcatechol (0.245 g, 2.00 mmol), and 4-
hydroxycoumarin (0.325 g, 2.00 mmol) in 1:1 THF/H2O (20.0 mL) was treated with K3Fe(CN)6 
(1.98 g, 6.00 mmol) and stirred for 2 h. The reaction mixture was extracted with EtOAc and 
concentrated in vacuo. The resultant crude solid was recrystallized from 1:1 EtOH/Ether to yield 
0.0976 g (0.346 mmol, 17.3%) of 8 as an orange powder: Mp 282.2 – 283.5 oC (dec.) 
(EtOH/Acetone); IR (neat) 3849, 3646, 3583, 3462, 3274, 2284, 1701 cm -1; 1H NMR (300 MHz, 
DMSO-d6) δ 9.79 (s, 1 H), 8.94 (s, 1 H), 8.03 (d, 1 H, J = 7.5 Hz), 7.61 (m, 1 H), 7.57 (d, 1 H, J 
= 7.5 Hz), 7.47 (t, 1 H, J = 7.5 Hz), 7.19 (s, 1 H), 2.40 (s, 3 H); 13C NMR (75 MHz, DMSO-d6) 
δ 157.7 and 157.6 (C-6 or C-11b), 152.3 (C-12), 149.1 (C-8), 144.2 (C-9). 144.2 (C-10a), 131.2 
(C-4), 124.9 (C-1), 121.2 (C-2), 117.1 (C-3), 113.0 and 112.5 (C-4a or C-6a), 108.6 (C-10), 
105.7 (C-11a), 101.9 (C-7), 9.0 (C-13); correlations observed in HMBC spectrum: C-1 (H-1), C-
2 (H-2), C-3 (H-3), C-4 (H-3, H-4), C-4a (H-1, H-3), C-6 (H-1, H-4), C-6a (H-1, H-3), C-7 (H-
7), C-8 (H-7, H-13), C-9 (H-7, H-13), C-10 (H-13), C-10a (H-3, H-4), C-11a (H-7), C-11b (H-1, 
H-4), C-12 (H-1, H-2, H-4), C-13 (H-13); MS (EI) m/z (rel intensity) 283 [M + 1]+ (31), 282 
[M]+ (100), 281 (15), 141 (6), 117 (7), 95 (6), 83 (8), 69 (13), 57 (17); HRMS (EI) m/z calcd for 
C16H10O5 282.0528, found 282.0525.  
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8,9-dihydroxy-2-methyl-6H-benzofuro[3,2-c]chromen-6-one (9) (JLV1055). A solution 
of NaOAc (0.329 g, 4.00 mmol), catechol (0.227 g, 2.00 mmol), and 4-Hydroxy-6-
methylcoumarin (0.352 g, 2.00 mmol) in 1:1 THF/H2O was treated with K3Fe(CN)6 (1.97 g, 6.00 
mmol) and stirred for 2 hr. The reaction mixture was extracted with EtOAc and concentrated in 
vacuo. The resultant crude mixture was recrystallized from 1:1 EtOH/Acetone to yield 0.139 g 
(0.492 mmol, 25%) of 9 as a light brown solid: Mp 280 oC (dec.) (EtOH/Acetone); IR (neat) 
3733, 3584, 2360, 2339, 1697, 1650, 1558, 1540, 1508, 1459, 1284 cm -1; 1H NMR (300 MHz, 
DMSO-d6) δ 9.63 (s, 1 H), 9.51 (s, 1 H), 7.82 (s, 1 H), 7.47 (s, 1 H), 7.28 (s, 1 H), 7.21 (s, 1 H), 
2.44 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 158.2, 158.0, 150.9, 149.9, 146.9, 145.1, 134.8, 
132.5, 121.0, 117.2, 114.3, 112.4, 105.8, 105.3, 99.3, 20.8; MS (EI) m/z 283 [M + 1]+ (37), 282 
[M]+ (100), 281 (18), 253 (100), 236 (7), 141 (7), 95 (8), 83 (10), 68 (12), 55 (17); HRMS (EI) 
m/z calcd for C16H10O5 282.0528, found 282.0527.  
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8,9-Dihydroxy-2,10-dimethyl-6H-benzofuro[3,2-c]chromen-6-one (10) (JLV1061). A 
solution of NaOAc (0.987 g, 12.0 mmol), 3-methylcatechol (0.748 g, 6.00 mmol), and 4-
Hydroxy-6-methylcoumarin (1.10 g, 6.00 mmol) in 1:1 THF/H2O (60.0 mL) was treated with 
K3Fe(CN)6  (5.93 g, 18.00 mmol) and stirred for 2 hr. The reaction mixture was extracted with 
EtOAc, dried (MgSO4), and concentrated in vacuo. The resultant crude mixture was 
recrystallized from 1:1 EtOH/Acetone to yield 0.547 g (1.85 mmol, 31%) of 10 as a brown solid: 
Mp 275 oC (dec.) (EtOH/Acetone); IR (neat) 3740, 3582, 3398, 2919, 1644, 1023 cm -1; 1H 
NMR (500 MHz, DMSO-d6) δ 9.78 (s, 1 H), 8.92 (s, 1 H), 7.77 (s, 1 H), 7.42 (s, 2 H), 7.16 (s, 1 
H), 2.42 (s, 3 H), 2.38 (s, 3 H); 13C NMR (125 MHz, DMSO-d6) δ 158.2 and 158.1 (C-6 or 11b), 
151.0 (C-12), 149.5 (C-10a), 144.6 and 144.6 (C-8 andC-9), 134.8 (C-2), 132.6 (C-1), 121.1 (C-
3), 117.3 (C-4), 113.5 and 112.6 (C-4a and C-6a), 109.0 (C-10), 106.1 (C-11a), 102.3 (C-7), 20.8 
(C-14), 9.5 (C-13); Observed HMBC correlations: C-1 (H-14), C-2  (H-3, H-4, H-14), C-3 (H-3, 
H-4, H-14), C-7 (H-8), C-8 (H-7, H-8, H-13), C-9 (H-7, H-9, H-13), C-11a (H-7), C-12 (H-1, H-
3, H-4), C-13 (H-13), C-14 (H-14); MS (EI) m/z (rel intensity) 298 [M + 2]+ (6), 297 [M + 1]+ 
(54), 296 [M]+ (100), 295 (26), 267 (9), 165 (14), 148 (20), 141 (29), 134 (13), 128 (10), 115 
(13), 105 (7), 77 (15), 63 (11); HRMS (EI) m/z calcd for C17H12O5 296.0685, found 296.0678.  
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    8,9-Dihydroxy-10-methoxy-2-methyl-6H-benzofuro[3,2-c]chromen-6-one (11)  
(JLV1066).39 A solution of NaOAc (0.328 g, 4.00 mmol), 3-methoxycatechol (0.300 g, 2.00 
mmol), 4-Hydroxy-6-methylcoumarin (0.353 g, 2.00 mmol) in 1:1 THF/H2O (20.0 mL) was 
treated with K3Fe(CN)6 (1.98 g, 6.00 mmol) and stirred for 2 hr. The reaction mixture was 
extracted with EtOAc, dried (MgSO4), and concentrated. The resultant crude mixture was 
triturated with 1:1 EtOH/Ether to yield 0.090 g (0.288 mmol, 15%) of 11 as an orange solid: Mp 
198 oC (dec.) (EtOH/Ether); IR (neat) 3583, 3367, 2917, 2849, 2360, 2339, 1650, 1576, 1540, 
1420, 1362, 1068 cm -1; 1H NMR (500 MHz, DMSO-d6) δ 9.64 (s, 1 H), 9.12 (s, 1 H), 7.85 (s, 1 
H), 7.45 (s, 2 H), 7.04 (s, 1 H), 4.07 (s, 3 H), 2.49 (s, 3 H); 13C NMR (125 MHz, DMSO-d6) 
δ 158.5 and 158.1 (C-6 or C-11b), 151.1 (C-12), 146.3 (C-8), 142.2 (C-10a), 138.6 (C-9), 135.0 
(C-2), 134.1 (C-10), 132.9 (C-1), 121.3 (C-4), 117.3 (C-3), 114.8, 112.5 (C-4a or C-6a), 105.9 
(C-11a), 99.8 (C-7), 61.1 (C-13), 20.8 (C-14); observed correlations in HMBC spectrum (H to 
C): C-1 (H-1), C-2 (H-3, H-4), C-3 and C-4 (H-3 or H-4), C-4a (H-3, H-4), C-6 (H-3, H-4), C-6a 
(H-1, H-3, H-4), C-7 (H-8), C-8 (H-7, H-8, H-9), C-9 (H-7, H-8, H-9), C-10 (H-7, H-9, H-13), 
C-10a (H-7),  C-11a (H-7), C-11b (H-1, H-3, H-4), C-12 (H-1, H-3, H-4, H-14), C-13 (H-13), C-
14 (H-14); MS (EI) m/z (rel intensity) 313 [M + 1]+ (14), 312 [M]+ (52), 297 (30), 296 (12), 269 
(10), 264 (13), 239 (15), 213 (8), 200 (5), 185 (8), 176 (28), 171 (12), 161 (20), 160 (45), 148 
(21), 141 (13), 135 (20), 134 (46), 129 (25), 123 (16), 117 (40), 109 (24), 105 (20), 97 (40), 91 
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(27), 85 (33), 83 (54), 81 (49), 77 (30), 71 (53), 69 (82), 67(40), 60 (21), 57 (100); HRMS (EI) 
m/z calcd for C17H12O6 312.0632, found 312.0634.  
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7,8-dihydroxy-3,3-dimethyl-3,4-dihydrodibenzo[b,d]furan-1(2H)-one (13)  
(JLV1081).46,108 A 1 L round bottom flask was charged with catechol (4.98 g, 45.3 mmol), 5,5-
dimethylcyclohexane-1,3-dione (9.52 g, 68.0 mmol), and NaHCO3 (4.20 g, 50.0 mmol) and 
dissolved in H2O (200 mL). To the stirred solution was added a solution of K3Fe(CN)6 (24.7 g, 
75.0 mmol) in H2O (200 mL) via an addition funnel. As the iron solution was added dropwise a 
blue color appeared and then disappeared with each drop and immediately precipitates began to 
form, turning the clear solution to a milky white. The reaction mixture was stirred for 3 hrs and 
the suspension was then vacuum filtered. The resultant solid was washed with water and 
recrystallized from 1:1 EtOH/Acetone to yield 4.68 g (19.0 mmol, 42%) of 13 as a white solid: 
Mp 180 oC (dec.) (EtOAc); IR (neat) 3848, 3814, 3583, 3305, 2922, 2852, 2359, 2048, 1646, 
1457, 1075 cm -1; 1H NMR (300 MHz, DMSO-d6) δ 9.12 (s, 2 H), 7.19 (s, 1 H), 6.97 (s, 1 H), 
2.87 (s, 2 H), 2.37 (s, 2 H), 1.08 (s, 6 H); 13C NMR (75 MHz, DMSO-d6) δ 193.7, 168.7, 148.4, 
144.4, 143.8, 114.5, 114.3, 105.4, 98.5, 51.6, 36.8, 35.0, 28.1; MS (ES) m/z (rel intensity) 247 
[M + 1]+ (14), 246 [M]+ (77), 237 (28), 208 (44), 199 (24), 190 (100), 162 (100), 134 (13), 115 
(16), 97 (25), 91 (29), 78 (39), 69 (70), 67 (35), 63 (23), 57 (91), 55 (100); HRMS (EI) m/z calcd 
for C14H14O4 246.0892, found 246.0885.  
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Formylidene protected 7,8-Dihydroxy-3,3-dimethyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one (14) (JLV1086). A solution of compound 13 (2.46 g, 10.0 mmol) and cesium 
carbonate (2.90 g, 15.0 mmol) in anhydrous DMF (24.0 mL) was treated with BrCH2Cl (1.0 mL, 
15.0 mmol) and refluxed for 4.5 h. Once cool, reaction mixture was poured over water and 
extracted with ether. The organic extracts were combined, dried (MgSO4), and concentrated in 
vacuo. The resultant solid was purified by flash chromatography on SiO2 (Rf = 0.40, CHCl3, 100 
%) to yield 0.600 g (2.32 mmol, 23%) of 14 as a white solid: Mp 250 oC (dec.) (CHCl3); IR 
(neat) 3818, 3742, 3672, 3583, 3366, 2920, 2361, 1663, 1457, 1135, 1040, 859 cm -1; 1H NMR 
(300 MHz, CDCl3) δ 7.39 (s, 1 H), 6.93 (s, 1 H), 5.98 (s, 2 H), 2.82 (s, 2 H), 2.31 (s, 2 H), 1.59 
(s, 6 H); 13C NMR (75 MHz, CDCl3) δ 194.2, 169.0, 150.0, 146.3, 145.5, 117.0, 115.7, 101.5, 
100.5, 93.6, 52.2, 37.8, 35.3, 28.7; MS (EI) m/z (rel intensity) 259 [M + 1]+ (18), 258 [M]+ (94), 
203 (19), 202 (74), 175 (17), 174 (100), 146 (13), 88 (10), 77 (9), 69 (13), 63 (9); HRMS (EI) 
m/z calcd for C14H14O4 258.0892, found 258.0893.  
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Moc-ethylidene acetal of 8,9-Dihydroxy-6H-benzofuro[3,2-c]chromen-6-one  (16) 
(JLV1113).48 A solution of compound 5 (0.300 g, 1.10 mmol) in CH3CN (10.0 mL) was treated 
with methyl propiolate (91 µL, 1.10 mmol) and DMAP (0.186 g, 1.5 mmol) and stirred at rt for 2 
h. The reaction mixture was concentrated in vacuo and the resultant crude residue was purified 
by flash chromatography on SiO2 (Rf = 0.50, Hex/EtOAc, 3:1) to yield 0.0750 g (0.204 mmol, 
21%) of 16 as a white solid: Mp 194.2 - 197.4 oC (Hexane/EtOAc); IR (neat) 2922, 2360, 2339, 
1738, 1626, 1508, 1469, 1360, 1272, 1148, 1070, 1030, 756 cm -1; 1H NMR (300 MHz, CDCl3) 
δ 7.92 (d, 1 H, J = 7.8 Hz), 7.53 (t, 1 H, J = 7.2 Hz), 7.45 (d, 1 H, J =7.5 Hz), 7.36 (t, 1 H, J =7.8 
Hz), 7.24 (s, 1 H), 7.10 (s, 1 H), 6.63 (t, 1 H, J = 5.1 Hz), 3.77 (s, 3 H), 3.05 (d, 2 H, J = 5.1 Hz); 
13C NMR (75 MHz, CDCl3) δ 168.5, 159.2, 158.1, 153.0, 151.0, 147.4, 145.9, 131.2, 124.6, 
121.3, 117.4, 117.0, 112.8, 109.2, 106.4, 94.1, 52.3, 40.0; MS (EI) m/z (rel intensity) 353 [M + 
1]+ (20), 352 [M] + (92), 320 (23), 303 (8), 292 (14), 279 (97), 268 (25), 267 (20), 265 (10), 239 
(10), 200 (16), 137 (13), 109 (13),  97 (25), 84 (84), 81 (47), 69 (100), 57 (66); HRMS (EI) m/z 
calcd for C19H12O7 353.0661, found 353.0689.  
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Moc-ethylidene acetal of 7,8-Dihydroxy-3,3-dimethyl-3,4-dihydrodibenzo[b,d]furan-
1(2H)-one (16) (JLV1103).48 A solution of compound 13 (0.481 g, 1.90 mmol) in CH3CN (15.0 
mL) was treated with methyl propiolate (200 µL, 2.41 mmol) and DMAP (0.3823 g, 2.28 mmol) 
and stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo and the 
resultant crude residue was purified by flash chromatography on SiO2 (Rf = 0.40, Hex/EtOAc, 
3:1) to yield 0.269 g (0.814 mmol, 43%) of 17 as white solid: Mp 149.1 - 151.3 oC 
(Hexane/EtOAc); IR (neat) 2955, 1743, 1670, 1497, 1464, 1437, 1403, 1305, 1272, 1134, 1087, 
1039 cm -1; 1H NMR (300 MHz, CDCl3) δ 7.39 (s, 1 H), 6.92 (s, 1 H), 6.62 (t, 1 H, J = 5.4 Hz), 
3.75 (s, 3 H), 3.06 (d, 2 H, J = 5.4 Hz), 2.83 (s, 2 H), 2.42 (s, 2 H), 1.16 (s, 6 H); 13C NMR (75 
MHz, CDCl3) δ 194.3, 169.2, 168.8 150.1, 145.9, 145.3, 117.2, 115.9, 108.7, 100.8, 93.8, 52.4, 
52.3, 40.1, 38.0, 35.5, 28.9, 28.8;  MS (EI) m/z (rel intensity) 331 [M + 1]+ (12), 330 [M]+ (65), 
279 (9), 274 (15), 258 (11), 257 (65),  246 (22), 231 (6), 213 (13), 185 (14), 157 (15), 149 (43), 
137 (85), 136 (53), 129 (33), 123 (48), 121 (53), 109 (48), 107 (36), 105 (24), 97(42), 95 (100); 
93 (64), 91 (52); HRMS (EI) m/z calcd for C18H18O6 330.1103, found 330.1097.  
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JLV1123 (20).49,50 8,9-dihydroxy-2-methyl-6H-benzofuro[3,2-c]chromen-6-one (9) 
(0.571 g, 2.0 mmol) was added to CH2Cl2 (10.0 mL) and THF (0.5 mL). The flask was cooled to 
-5 oC and DMAD (250 µL, 2.0 mmol) was added via syringe. The reaction mixture was stirred 
for 5 min and then t-Butyl isocyanide (191 µL, 2.0 mmol) was added dropwise slowly and stirred 
for 10 min at -5 oC before warming to rt. The reaction was stirred at rt for 48 h and concentrated. 
The crude mixture was purified by flash chromatography on SiO2 (Rf = 0.20, Hex/EtOAc, 4:1) to 
yield 0.301 g (0.594 mmol, 30%) of 20 as a white solid: Mp 153.0 – 156.0 oC (CH2Cl2); IR 
(neat) 3582, 3367, 2923, 1740, 1664, 1616, 1476, 1435, 1380, 1318, 1258, 1209, 1134, 1073, 
1031 cm -1; 1H NMR (500 MHz, CDCl3) δ 9.10 (br s, 1 H), 7.83 (s, 1 H), 7.79 (s, 1 H), 7.40 (s, 1 
H), 7.34 (s, 1 H), 5.92 (s, 1 H), 3.77 (s, 3 H), 3.75 (s, 3 H), 2.49 (s, 3 H) 1.59 (s, 9 H), 1.53 (s, 9 
H); 13C NMR (125 MHz, CDCl3) δ 170.7, 169.6 (C-20 and C-21), 169.3 (C-10), 160.9 (C-6), 
158.3 (C-17b), 153.2 (C-16), 151.9 (C-4a), 147.0 (C-6a), 141.3 (C-14), 134.9 (C-2), 133.2 (C-
18), 121.6 (C-4), 117.4 (C-3), 114.0 (C-13), 112.4 (C-1), 105.9 (C-8), 103.7 (C-15), 82.4 (C-11), 
73.5 (C-9), 53.5, 52.9 (C-22 and C-23), 51.6 (C-25), 31.2 (C-24), 21.2 (C-19); Relevant HMBC 
correlations: C-6a [H-1, H-9, H-15]; MS (EI) m/z 507 (M+,10), 448 (100), 392 (96), 360 (45), 
349 (30), 281 (55), 261 (5), 138 (6), 91 (10), HRMS (EI) m/z calcd for C27H25NO9 507.1529, 
found 507.1537.  
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1,1'-(6,6'-(2-Hydroxypropane-1,3-diyl)bis(oxy)bis(2-hydroxy-6,1-
phenylene))diethanone (30). A solution of 2,6-dihydroxyacetophenone (28) (9.70 g, 64.0 
mmol) and epichlorohydrin (29) (2.67 mL, 33.8 mmol) was dissolved in hot i-PrOH (250 mL) 
and heated to 80 oC. To the reaction mixture was added a solution of KOH (2.3 g, 40.2 mmol) in 
i-PrOH (25.0 mL) and H2O (1.0 mL). After refluxing for 46 h, H2O (50.0 mL) was added to the 
cooled reaction mixture. The resultant precipitate was filtered off and washed with ether and 
water and the resultant solid was recrystallized from hot i-PrOH and dried under vacuum 
overnight to give product 4.4 g (12.2 mmol, 36%) of 30 as a light tan solid: Mp 163.0 – 170.0 oC 
(CH2Cl2); IR (ATR) (neat) 3517, 3511, 3490, 2944, 2939, 2915, 2626, 1618, 1593, 1446, 1364, 
1346, 1251, 1234, 1176, 1105, 1083, 1070, 1020, 956 cm-1; 1H NMR (300 MHz, DMSO-d6) 
δ 7.32 (t, 2 H, J = 8.1 Hz), 6.57 (d, 2 H, J = 8.4 Hz), 6.50 (d, 2 H, J = 8.1 Hz), 5.49 (d, 1 H, J = 
4.8 Hz), 4.25 (m, 1 H), 4.12 (m, 4 H), 2.57 (s, 6 H); 13C NMR (75 MHz, DMSO-d6) δ 204.0, 
160.4, 159.0, 134.5 113.8, 109.6, 103.0, 70.3, 67.1, 33.3; MS (EI) m/z (rel intensity) 360 [M]+ 
(25), 342 (26), 209 (8), 196 (40), 165 (87), 137 (100), 107 (24), 69 (23); HRMS (EI) m/z calcd 
for C19H20O7 360.1209, found 360.1213.  
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Diethyl-5,5'-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-
carboxylate) (32).54,55 Sodium metal (0.459 g, 19.9 mmol) was dissolved in EtOH (10.0 mL) 
and heated to reflux. To the hot solution was added solid bis-phenol 30 (0.720 g, 1.99 mmol) and 
diethyl oxalate (31) (1.66 mL, 11.9 mmol) and refluxed for 20 h. Once cooled, the reaction 
mixture was poured into ether and filtered. The resultant solid was added to water (12.0 mL) and 
acidified with 1.0 M HCl. The aqueous mixture was extracted with CH2Cl2 and the organic 
extracts were combined, dried (MgSO4) and concentrated in vacuo. To the resultant residue was 
added conc. HCl (0.500 mL) and heated in an oil bath for 5 min. The reaction mixture was 
filtered and solids were recrystallized with 1:1 EtOH/Benzene (6.0 mL). The resultant brown 
solid product was dried under vacuum overnight to give 0.490 g (0.935 mmol, 47%) of 32 as a 
brown solid: Mp 180.0 – 185.1 oC (EtOH); IR (ATR) (neat) 3459, 3466, 3097, 3082, 2611, 2380, 
2397, 1733, 1640, 1616, 1599, 1569, 1560, 1474, 1457, 1450, 1388, 1264, 1241, 1215, 1124, 
1073, 1049, 1012, 950, 868 cm-1; 1H NMR (300 MHz, DMSO-d6) 7.71 (t, 2H, J= 8.4 Hz), 7.13 
(dd, 4H, J= 19.8, 8.4 Hz), 6.67 (s, 2H), 4.28 (m, 8H), 1.32 (t, 6H, J= 5.7 Hz); MS (EI) m/z (rel 
intensity) 524 [M]+ (15), 496 (14), 368 (7), 234 (9), 206 (13), 121 (22), 97 (27), 83 (40), 69 (75), 
57 (100); HRMS (EI) m/z calcd for C27H24O11 524.1319, found 524.1329. 
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2-(Chloromethyl)-2-methyloxirane (34).56 A solution of 3-chloro-2-methylpropene (33) 
(5.4 mL, 49.7 mmol) in dry CH2Cl2 (100 mL) was treated with m-CPBA (8.57 g, 50.0 mmol) and 
stirred at RT overnight. The reaction mixture was washed with saturated sodium bicarbonate 
solution (4 x 25.0 mL) and brine and dried (MgSO4). The clear colorless liquid was carefully 
concentrated in vacuo until about 6.0 mL of liquid remaining and distilled (50 oC) to give 5.10 g 
(47.8 mmol, 96%) of 34 as a clear colorless liquid: 1H NMR (300 MHz, CDCl3) δ 3.52 (dd, 2 H, 
J = 16.5, 11.4 Hz), 2.78 (dd, 2 H, J = 15.9, 4.8 Hz), 1.48 (s, 3 H); MS (EI) m/z (rel intensity) 106 
[M]+ (20), 86 (24), 84 (37), 79 (32), 77 (100), 71 (21), 57 (24); HRMS m/z calcd for C4H7OCl 
106.0185, found 106.0184. 
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1,1'-(6,6'-(2-Hydroxy-2-methylpropane-1,3-diyl)bis(oxy)bis(2-hydroxy-6,1-
phenylene))diethanone (35). A solution of 2’,6’-dihydroxyacetophenone (28) (2.0 g, 13.1 
mmol) and 2-methyl-epichlorohydrin (34) (0.742 mL, 7.0 mmol) in hot i-PrOH (50.0 mL) was 
treated with a solution of KOH (0.465 g, 8.28 mmol) in i-PrOH (5.0 mL) and H2O (1.0 mL). The 
reaction mixture was refluxed for 48 h and once cooled H2O (50.0 mL) was added. The 
precipitates was filtered off and washed with ether and H2O. The resultant solid was 
recrystallized from i-PrOH to give 0.784 g (2.09 mmol, 30%) of 35 as a tan colored solid: Mp 
 75 
171.2 – 177.0 oC (EtOH); IR (ATR) (neat) 3463, 1618, 1590, 1457, 1446, 1418, 1362, 1340, 
1299, 1282, 1230, 1191, 1178, 1103, 1075, 1029, 958, 943 cm-1; 1H NMR (300 MHz, DMSO-d6) 
δ 11.7 (s, 2 Η),  7.29 (t, 2 H, J = 8.1 Hz), 6.56 (d, 2 H, J = 8.4 Hz), 6.49 (d, 2 H, J = 8.1 Hz), 
5.18 (s, 1 H), 4.01 (d, 2 H, J = 10.8 Hz), 3.94 (d, 2 H, J = 9.3 Hz), 2.53 (s, 6 H), 1.31 (s, 3 H); 
13C NMR (75 MHz, DMSO-d6) δ 203.6, 159.7, 158.6, 134.1 114.3, 109.6, 103.0, 73.2, 70.2, 
33.2, 22.6; MS (ES) m/z (rel intensity) 398 [M + 1 + Na] + (3), 397 [M + Na]+ (100), 398, 365 
(3), 212 (4), 195 (5), 119 (5); HRMS (ES) m/z calculated for C20H22O7Na 397.1263, found 
397.1300.  
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Diethyl-5,5'-(2-hydroxy-2-methylpropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-
2-carboxylate) (36). Sodium metal (0.122 g, 5.3 mmol) was dissolved in EtOH (7.0 mL) and 
heated to reflux. To the hot solution was added solid bis-phenol 35 (0.200 g, 0.534 mmol) and 
diethyl oxalate (31) (0.443 mL, 3.2 mmol). After refluxing for 20 h, the cooled reaction mixture 
was poured into ether and filtered. The solid was then added to water (6.0 mL) and acidified with 
1M HCl (1.0 mL). The aqueous mixture was extracted with CH2Cl2. The organic extracts were 
combined and concentrated. To this resultant residue was added conc. HCl (0.5 mL) and heated 
in an oil bath for 5 min. The mixture was filtered and solid residue was purified by column 
chromatography on SiO2 (Rf  = 0.26, CH2Cl2/MeOH, 95:5) to give 0.115 g (0.534 mmol, 41%) of 
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36 as a brown oil: IR (ATR) (neat) 3468, 3458, 3090, 2976, 2980, 1735, 1646, 1603, 1476, 1450, 
1249, 1219, 1105, 1073 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 7.57 (t, 2 H, J = 8.4 Hz), 7.13 
(d, 2 H, J = 8.4 Hz), 6.96 (s, 2 H), 6.90 (d, 2 H, J = 8.1 Hz), 4.45 (q, 4 H, J = 13.8, 6.9 Hz), 4.45 
(d, 2 H, J = 8.7 Hz), 4.12 (d, 2 H, J = 8.7 Hz), 1.53 (s, 3 H), 1.42 (t, 6 H, J = 6.9 Hz);  13C NMR 
(75 MHz, DMSO-d6) δ 178.4, 160.4, 158.7, 157.6, 135.0, 116.1, 115.3, 110.8, 109.2, 73.3, 71.3, 
63.0, 21.4, 14.1; MS (ES) m/z (rel intensity) 562 [M + 1 + Na]+ (5), 561 [M + Na]+ (100); HRMS 
(ES) m/z calcd for C28H26O11Na 561.1373, found 561.1344.  
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2-(Chloromethyl)-2-phenyloxirane (38).56,57 A solution of benzoyl chloride (37) (1.65 
mL, 14.2 mmol), LiBr (2.84 g, 32.7 mmol), chloroiodomethane (2.43 mL, 32.7 mmol) in dry 
THF (60.0 mL) was cooled to -78 oC and treated with n-BuLi (27.3 mL) dropwise over 20 min. 
After stirring for 1 h at -78 oC, the reaction mixture was warmed to rt and then concentrated in 
vacuo. The resultant red-orange residue was dissolved in hexanes and washed with saturated 
NH4Cl solution, saturated sodium thiosulfate solution and brine. The organic extracts were dried 
(Na2SO4) and concentrated in vacuo. The residual solvent was then distilled (70 oC) out of the 
reaction mixture to give 1.96 g (11.6 mmol, 82%) of 38 as an orange liquid: 1H NMR (500 MHz, 
CDCl3) δ 7.45 (m, 2 H), 7.38 (m, 3 H), 4.06 (d, 1 H, J = 7.2 Hz), 3.86 (d, 1 H, J = 7.2 Hz), 3.22 
(d, 1 H, J = 3.0 Hz), 2.94 (d, 1 H, J = 3.3 Hz); MS (EI) m/z (rel intensity) 170 [M + 2]+ (36), 169 
[M + 1] + (48), 168 [M] + (93), 167 (100), 163 (30), 133 (11), 105 (14), 104 (27), 103 (46), 91 
(22), 96 (21); HRMS (EI) m/z calcd for C9H9OCl 168.0342, found 168.0350. 
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1,1'-(6,6'-(2-Hydroxy-2-phenylpropane-1,3-diyl)bis(oxy)bis(2-hydroxy-6,1-
phenylene))diethanone (39). A solution of 2,6-Dihydroxyacetophenone  (28) (2.0 g, 13.1 mmol) 
and 2-phenyl-epichlorohydrin (38) (1.2 mL, 7.0 mmol) in hot i-PrOH (50.0 mL) was heated to 
reflux and treated with a solution of KOH (0.465 g, 8.28 mmol) in i-PrOH (5.0 mL) and H2O 
(0.5 mL). After refluxing for 48 h, H2O (50.0 mL) was added to the cooled reaction mixture. The 
resultant precipitate was filtered off and washed with ether and H2O. The crude residue was 
recrystallized from i-PrOH to give 0.632 g (1.49 mmol, 21%) of 39 as a tan solid: Mp 165.0 oC 
(dec) (CH2Cl2); IR (ATR) (neat) 3474, 3494, 2956, 2928, 2892, 2874, 2635, 1616, 1590, 1576, 
1454, 1437, 1366, 1344, 1301, 1224, 1101, 1083 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 11.9 (s, 
2 H), 7.62 (d, 2 H, J = 7.5 Hz), 7.34 (m, 5 H), 6.58 (d, 2 H, J = 8.4 Hz), 6.49 (d, 2 H, J = 9.0 Hz), 
5.95 (s, 1 H), 4.38 (s, 4 H), 2.27 (s, 6 H); 13C NMR (75 MHz, DMSO-d6) δ 204.3, 160.5, 159.1, 
142.7, 134,8, 128.3, 127.6, 126.5, 114.2, 110.1, 103.3, 74.9, 74.1, 33.4; MS (ES) m/z (rel 
intensity) 460 [M + 1 + Na]+ (5), 459 [M + Na]+ (100), 425 (5), 316 (5); HRMS (ES) m/z calcd 
for C25H24O7Na 459.1420, found 459.1444. 
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Diethyl 5,5'-(2-hydroxy-2-phenylpropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-
2-carboxylate) (40). Sodium metal (0.184 g, 8.01 mmol) was dissolved in EtOH (10.0 mL) and 
heated to reflux. To the hot solution was added 39 (0.350 g, 0.801 mmol) and diethyl oxalate 
(31) (0.666 mL, 4.81 mmol) and refluxed for 20 h. Once cooled, the reaction mixture was poured 
into ether and filtered. The solid was then added to water (6.0 mL) and acidified with 1 M HCl 
(1.0 mL). The aqueous mixture was extracted with CH2Cl2 and the organic extracts were 
combined and concentrated. To this resultant residue was added conc. HCl (0.5 mL) and heated 
in an oil bath. After 5 min, the solid was filtered and collected. The resultant residue was purified 
by column chromatography on SiO2 (Rf = 0.10, CH2Cl2/MeOH 98:2) to give 0.0203 g (0.0340 
mmol, 4.2%) of 40 as a white film: IR (ATR) (neat) 3479, 3468, 3492, 3455, 3081, 2959, 2928, 
1733, 1629, 1606, 1569, 1457, 1449, 1437, 1418, 1384, 1362, 1327, 1251, 1062 cm-1; 1H NMR 
(300 MHz, DMSO-d6) δ 8.02 (d, 2H, J= 8.4 Hz), 7.57 (t, 2H, J= 8.4 Hz), 7.39 (t, 3H, J= 6.9 Hz), 
7.14 (d, 2H, J= 8.4 Hz), 7.00 (s, 2H), 6.93 (d, 2H, J= 8.1), 4.88 (d, 2H, J= 8.7), 4.46 (q, 4H, J= 
7.2, 14.1 Hz), 4.36 (d, 2H, J= 8.7 Hz), 1.44 (t, 6H, 6.9); 13C NMR (75 MHz, DMSO-d6) 
δ 178.3, 160.5, 158.6, 157.6, 150.7, 134.9, 128.4, 128.2, 125.8, 127.6, 125.8, 116.3, 115.5, 111.0,
 109.6, 73.8, 63.0, 14.1; MS (ES) m/z (rel intensity) 624 [M + 1+ Na]+ (10), 623 [M + Na]+ 
(100); HRMS (ES) m/z calcd for C33H28O11Na 623.1529, found 623.1487. 
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1-(2-Hydroxy-4,6-bis(methoxymethoxy)phenyl)ethanone (42).59,60,109 A solution of 
2,4,6-trihydroxyacetophenone (41) (13.0 g, 77.3 mmol) in CH2Cl2 (200 mL) was cooled to 0 oC. 
To the reaction mixture was added DIPEA (28.2 mL, 162.4 mmol) and stirred for 15 min. Then 
MOMCl solution61 (24.7 mL, 162 mmol) was added dropwise at 0 oC and allowed to warm to rt. 
The reaction mixture was stirred for 3 h and poured into H2O. The reaction mixture extracted 
with CHCl3 and the organic extracts were combined, washed with water and brine and then dried 
(MgSO4). The reaction mixture was then concentrated in vacuo and resultant orange oil was 
filtered through a pad of silica gel (Rf = 0.40, 4:1 Hex/EtOAc; Hex/EtOAc, 9:1) to give 5.7 g 
(22.2 mmol, 29%) of 42 as a white solid: Mp 44.3 - 49.1 oC; IR (ATR) (neat) 3129, 3110, 2959, 
2945, 2937, 1612, 1590, 1411, 1415, 1360, 1265, 1219, 1206, 1165, 1077, 1062, 1023, 941, 926 
cm-1; 1H NMR (300 MHz, CDCl3) δ 13.7 (s, 1 H), 6.26 (d, 1 H, J = 2.4 Hz), 6.24 (d, 1 H, J = 2.4 
Hz), 5.25 (s, 2 H), 5.17 (s, 2 H), 3.52 (s, 3 H), 3.47 (s, 3 H), 2.65 (s, 3 H); 13C NMR (75 MHz, 
CDCl3) 203.3, 166.8, 163.5, 160.4, 106.9, 97.1, 94.5, 94.0, 56.7, 56.5, 33.1; MS (EI) m/z (rel 
intensity) 257 [M + 1]+ (14), 256 [M]+ (100), 211 (9), 182 (100), 152 (11), 86 (62), 84 (100), 69 
(24), 57 (34); HRMS (EI) m/z calcd for C12H16O6 256.0947, found 256.0939.  
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1-(2,6-Dihydroxy-4-(methoxymethoxy)phenyl)ethanone (42).58-60 A solution of MOM-
ether 42 (5.2 g, 20.3 mmol) in MeOH (200 mL) was treated with iodine (2.0 g, 7.87 mmol, 1% 
w/v) and stirred at rt for 17 h. The reaction mixture was quenched with sodium thiosulfate 
solution and extracted with ether. The organic extracts were washed with brine, dried (MgSO4), 
and concentrated in vacuo. The resultant residue was purified by column chromatography on 
SiO2 (Rf = 0.30 Hex/EtOAc 4:1, Hex/EtOAc, 4:1, 1:1) to give 1.79 g (8.44 mmol, 42%) of 43 as 
a yellow solid: Mp 119.5 – 125.4 oC (CH2Cl2); IR (ATR) (neat) 3278, 3271, 3259, 3254, 3014, 
2973, 2931, 1620, 1582, 1433, 1359, 1277, 1249, 1221, 1215, 1142, 1066, 1055, 952 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 6.08 (s, 2 H), 5.16 (s, 2 H), 3.47 (s, 3 H), 2.70 (s, 3 H), 1.90 (s, 2 H); 
13C NMR (75 MHz, CDCl3) δ 203.7, 163.3, 105.8, 96.0, 94.0, 56.4, 32.8; MS (EI) m/z (rel 
intensity) 213 [M + 1]+ (13), 212 [M]+ (100), 197 (12), 180 (22), 167 (40), 152 (20), 138 (32), 
121 (7), 84 (15), 68 (31); HRMS (EI) m/z calcd for C10H12O5 212.0685, found 212.0683.   
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1,1'-(6,6'-(2-Hydroxypropane-1,3-diyl)bis(oxy)bis(2-hydroxy-4-(methoxymethoxy)-
6,1-phenylene))diethanone (43). To a 100 mL round-bottom flask was added MOM-ether 41 
(1.69 g, 7.99 mmol) and epichlorohydrin (29) (0.335 mL, 4.24 mmol) and dissolved in hot i-
PrOH (30.0 mL). The reaction mixture was heated to reflux and to the solution was added a 
solution of KOH (0.282 g, 5.0 mmol) in i-PrOH (5.0 mL) and H2O (1.0 mL). The reaction 
mixture was refluxed for 46 h and once cooled H2O (50.0 mL) was added. The precipitate was 
filtered off and washed with ether and H2O. The resultant solid was recrystallized from hot i-
PrOH and dried overnight to give 0.630 g (1.31 mmol, 31%) of 44 as a pale yellow solid: Mp 
149.2 – 157.6 oC (EtOH); IR (ATR) (neat) 3567, 3574, 3120, 3110, 2954, 2924, 2907, 1610, 
1586, 1444, 1428, 1413, 1362, 1262, 121, 1148, 1126, 1109, 1087, 1060, 1021, 937 cm-1; 1H 
NMR (300 MHz, DMSO-d6) 13.6 (S, 2H), 7.35 (s, 2H), 6.22 (d, 2H, J= 1.8 Hz), 6.14 (d, 2H, J= 
2.1 Hz), 5.25 (s, 4H), 4.33 (br s, 1H), 4.16 (m, 4H), 3.37 (s, 6H), 2.63 (s, 6H); MS (EI) m/z (rel 
intensity) 481 [M + 1]+ (10), 480 [M]+ (30), 462 (6), 416 (9), 361 (11), 342 (9), 319 (10), 268 
(14), 251 (17), 225 (37), 195 (43), 181 (67), 165 (65), 153 (47), 121 (22), 105 (13), 77 (21), 69 
(35); HRMS m/z calcd for C23H28O11 480.1632, found 480.1628. 
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2-Bromo-1-(2,5-dimethoxyphenyl)ethanone (82).110 A 500 mL flame dried round 
bottom flask was charged with 2’,5’-dimethoxyacetophenone (81) (50.0 g, 275 mmol) and 
diluted with a solution of 2:1 diethyl ether/1,4-dioxane (150 mL). As the reaction was stirred 
bromine (14.2 mL, 275 mmol) was added dropwise via an addition funnel over 30 min. Stirring 
continued for 1h after the addition was complete and the reaction mixture was partitioned 
with H2O and extracted with ether. The organic extracts were dried (MgSO4) and 
concentrated to give crude product 82 as grayish-white solid. The crude solid was clean 
by 1H NMR and carried on to next reaction without purification: 1H NMR (300 MHz, 
CDCl3) δ 7.38 (d, 1 H, J = 3.3 Hz), 7.10 (dd, 1 H, J = 9.0, 3.3 Hz), 6.95 (d, 1 H, J = 9.0 Hz), 4.64 
(s, 2 H), 3.93 (s, 3 H), 3.82 (s, 3 H); MS (EI) m/z (rel intensity) 260 [M + 2]+ (66), 258 [M]+ (67), 
244 (50), 243 (52), 166 (10), 165 (100), 150 (5), 122 (7), 107 (7), 92 (6), 77 (9), 63 (5); HRMS 
(EI) m/z calcd for C10H11BrO3 257.9892, found 257.9889.      
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S-2-(2,5-Dimethoxyphenyl)-2-oxoethyl-O-ethylcarbonodithioate (84).100 A solution of 
compound 82 (65.2 g, 251 mmol) in acetone (500 mL) was cooled to 0 oC and treated with 
potassium ethyl xanthate (83) (41.2 g, 257 mmol).  After stirring at rt for 5 h. The 
reaction mixture was concentrated and the resultant residue was partitioned with H2O/ 
CH2Cl2. The organic extracts were combined, washed with H2O and then dried (MgSO4) 
and concentrated. The resultant residue was recrystallized with CH2Cl2/Hexanes to give 
68.0 g (226 mmol, 90%) of 84 as yellow/brown solid: 1H NMR (300 MHz, CDCl3) δ 7.32 
(d, 1 H, J = 3.3 Hz), 7.08 (dd, 1 H, J = 9.2, 3.3 Hz), 6.94 (d, 1 H, J = 9.3 Hz), 4.62 (q, 2 H, J = 
7.2 Hz), 4.62 (s, 2 H), 3.92 (s, 3 H), 3.80 (s, 3 H), 1.40 (dd, 3 H, J = 7.2, 7.2 Hz); MS (EI) m/z 
(rel intensity) 300 [M]+ (15), 267 (7), 243 (10), 211 (6), 166 (10), 165 (100), 122 (5), 107 (7), 77 
(5), 57 (7); HRMS (EI) m/z calcd for C13H16O4S2 300.0490, found 300.0482.      
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5,8-Dimethoxy-4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl pivalate (86).100 A solution 
of xanthate 84 (83.0 g, mmol) in 1,2-dichloroethane (400 mL) was treated with vinyl 
pivalate (85) (71.5 mL, mmol) and heated to reflux. After refluxing for 15 min, lauroyl 
peroxide (DLP) (11.2 mL, mmol) was added to the reaction mixture. Two additional 
portions of DLP (5.6 g, mmol) were added every 1.5 h. Refluxing continued for 2 h after 
the final addition of DLP and the reaction flask was cooled to room temperature and 
concentrated on the rotary evaporator. The resultant crude mixture was dissolved in 1,2-
dichloroethane (800 mL) and the reaction mixture was heated to reflux again. DLP (92.0 
g, 231 mmol) was added portion-wise over 5 h (18.4 g every 1 hour). After a total of 6 
hrs of refluxing, the reaction mixture was cooled to rt and then in an ice water bath (20 
min). The reaction mixture was concentrated in vacuo and the crude reaction mixture was 
purified via flash chromatography on SiO2 (Rf = 0.50, Hex/EtOAc 9:1, 4:1, 1:1) to give 
31.1 g (226 mmol, 41%) of 86 as a dark red oil/foam over the two steps: 1H NMR (300 
MHz, CDCl3) δ 7.08 (d, 1 H, J = 9.3 Hz), 7.0 (d, 1 H, J = 9.0 Hz), 6.34 (t, 1 H, J = 2.7 Hz), 3.89 
(s, 3 H), 3.80 (s, 3 H), 2.85 (ddd, 1 H, J = 16.8, 5.1, 5.1 Hz), 2.56 (ddd, 1 H, J = 16.8, 16.8, 4.8 
Hz), 2.36 (dddd, 1 H, J = 14.7, 14.4, 3.0, 2.7 Hz), 2.20 (ddd, 1 H, J = 15.0, 14.1, 3.6, 3.3 Hz), 
1.20 (s, 9 H); MS (EI) m/z (rel intensity) 307 [M + 1]+ (6), 306 [M]+ (30), 221 (10), 206 (11), 
 85 
205 (72), 194 (7), 177 (12), 137 (12), 95 (12), 86 (67), 84 (100), 81 (40), 73 (16), 69 (87), 60 
(15), 57 (56); HRMS (EI) m/z calcd for C17H22O5 306.1467, found 306.1464.     
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2-Bromo-5,8-dimethoxynaphthalen-1-ol (87).100,111 A solution of pivalate 86 (14.0 
g, 38.8 mmol) in dry CH2Cl2 (200 mL) was cooled to 0 oC for 10 min and treated with 
pyridinium bromide perbromide (3.28 g, 38.8 mmol). The reaction mixture was stirred at 
0 oC for 2.5 h and diluted with CH2Cl2. The reaction mixture was washed with saturated 
sodium thiosulfate solution and the organic extracts were dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via flash column chromatography 
on SiO2 (Rf = 0.65, Hex/EtOAc, 4:1) to give 5.20 g (18.4 mmol, 47%) of 87 as brown 
solid: Mp 125.0-136.3 oC (EtOAc); IR (ATR) (neat) 3330, 2940, 2838, 1610, 1504, 1454, 1390, 
1299, 1253, 1165, 1151, 1126, 1088, 1050 cm -1; 1H NMR (300 MHz, CDCl3) 
δ 10.2 (s, 1 Η), 7.60 (d, 1 Η, J = 9.0 Hz), 7.54 (d, 1 H, J = 9.0 Hz), 6.71 (d, 1 H, J = 8.4 Hz), 6.64 
(d, 1 H, J = 8.4 Hz), 4.01 (s, 3 H), 3.93 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 151.1, 151.0, 
149.7, 131.4, 127.8, 116.7, 114.8, 106.1, 105.4, 104.1, 57.2, 56.3; MS (EI) m/z (rel intensity) 283 
[M]+ (62), 282 (63), 269 (62), 267 (66), 254 (12), 218 (18), 204 (23), 189 (29), 165 (14), 132 
(20), 115 (15), 97 (22), 87 (100), 81 (29), 73 (47), 69 (64), 60 (44), 57 (78), 55 (71); HRMS (EI) 
m/z calcd for C12H11BrO3 281.9892, found 281.9880.     
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2-Bromo-5,8-dimethoxy-1-(methoxymethoxy)naphthalene (88). A solution of 
bromide 87 (5.20 g, 18.4 mmol) in dry THF (75.0 mL) was cooled to 0 oC and treated 
with sodium hydride (1.17 g, 48.8 mmol). The reaction was stirred for 30 min at 0 oC and 
then MOMCl solution (6.98 mL, 46.0 mmol) was added dropwise via syringe. The 
reaction mixture was warmed to rt and stirred for 15 h. The reaction was quenched with 
saturated NH4Cl solution and extracted with EtOAc. The organic extracts were dried 
(MgSO4) and concentrated in vacuo. The resultant residue was purified via flash 
chromatography on SiO2 (Rf = 0.70, Hex/EtOAc, 9:1) to give 4.90 g (15.0 mmol, 82%) of 
88 as orange/brown oil: IR (neat) 2993, 2937, 2916, 2833, 2799, 1616, 1579, 1454, 1439, 
1413, 1401, 1340, 1316, 1305, 1256, 1237, 1211, 1193, 1159, 1137, 1087, 1040, 978, 952 cm -1; 
1H NMR (300 MHz, CDCl3) δ 7.92 (d, 1 H, J = 9.0 Hz), 7.61 (d, 1 H, J = 9.0 Hz), 6.81 (d, 1 H, J 
= 8.7 Hz), 6.73 (d, 1 H, J = 8.4 Hz), 5.13 (s, 2 H), 3.94 (s, 3 H), 3.91 (s, 3 H), 3.75 (s, 3 H); 13C 
NMR (75 MHz, CDCl3) δ 150.5, 149.9, 149.5, 130.7, 128.7, 122.6, 120.4, 117.1, 108.1, 104.9, 
101.6, 59.0, 57.5, 56.4; MS (EI) m/z (rel intensity) 328 [M + 2] + (60), 327 [M +1]+ (60), 297 
(25), 296 (25), 284 (14),  281 (23), 267 (17), 248 (24), 247 (100), 232 (11), 215 (30), 202 (34), 
195 (23), 187 (38), 174 (53), 156 (15), 115 (17), 101 (12), 69 (13); HRMS (EI) m/z calcd for 
C14H15BrO4 326.0154, found 326.0143.     
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5,8-Dimethoxy-1-(methoxymethoxy)-2-naphthaldehyde (79). A solution of compound 
88 (3.50 g, 10.7 mmol) in dry THF (40.0 mL) was cooled to -78 oC and treated with a 1.7 M 
solution of t-butyl lithium (17.0 mL, 28.9 mmol). After stirring for 1 hr at -78 oC, anhydrous 
DMF (5.22 mL, 67.4 mmol) was added dropwise and stirred at -78 oC for 30 min and then 
warmed to rt. The reaction mixture was cooled to 0 oC and quenched with saturated NH4Cl 
solution and extracted with EtOAc. The organic extracts were washed with brine, dried 
(MgSO4), and concentrated in vacuo. The resultant residue was purified via flash 
chromatography on SiO2 (Rf = 0.75, Hex/EtOAc, 3:1) to give 1.31 g (9.63 mmol, 49%) of 
73 as a yellow gum: IR (neat) 2934, 2855, 2360, 1738, 1681, 1617, 1602, 1581, 1509, 1459, 
1415, 1349, 1260, 1234, 1156, 1104, 1050 cm -1; 1H NMR (300 MHz, CDCl3) δ 10.6 (s, 1 H), 
8.11 (d, 1 H, J = 8.7 Hz), 7.87 (d, 1 H, J = 9.0 Hz), 6.90 (d, 1 H, J = 8.7 Hz), 6.85 (d, 1 H, J = 8.4 
Hz), 5.20 (s, 2 H), 3.97 (s, 6 H), 3.61 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 192.0, 159.7, 151.2, 
150.3, 132.3, 128.3, 123.0, 120.6, 119.7, 107.9, 107.5, 102.8, 58.8, 57.2, 56.6; MS (EI) m/z (rel 
intensity) 277 [M + 1]+ (18), 276 [M]+ (100), 264 (10), 245 (18), 232 (90), 231 (85), 230 (40), 
217 (92), 216 (61), 202 (82), 201 (65), 187 (28), 175 (39), 143 (19), 115 (48), 97 (29), 89 (33), 
81 (41), 71 (44), 63 (26), 57 (92); HRMS (EI) m/z calcd for C15H16O5 276.0998, found 276.0998.  
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2-Iodoresorcinol (111).112 A 250 mL round bottom flask was equipped with large 
elliptical stir bar and open to the atmosphere was charged with distilled water (46.0 mL), 
resorcinol 107 (7.27 g, 66.0 mmol) and iodine (17.9 g, 70.6 mmol), and placed in an ice-
water bath. The reaction mixture was stirred vigorously and NaHCO3 (6.15 g, 73.3 
mmol) was added portion-wise via spatula (50.0 mg every 5-10 seconds) over 5 minutes 
(CO2 gas evolution was observed upon addition). The ice bath was removed and the 
reaction mixture was warmed to rt over 20 min and stirred for an additional 10 min. The 
reaction mixture was extracted with EtOAc and combined organic extracts were washed 
with 10% sodium thiosulfate and brine, dried (Na2SO4) and concentrated in vacuo. The 
resultant solid was triturated with CHCl3 (20.0 mL) for 10 min at -10 oC (EtOH/ice bath), 
filtered, and washed with cold CHCl3 to give 8.40 g (35.6 mmol, 54%) of 2-
iodoresorcinol (111) as a cream-colored solid: 1H NMR (300 MHz, CDCl3) δ 8.87 (br s, 2 
H), 7.00 (t, 1 H, J = 8.1 Hz), 6.47 (d, 2 H, J = 8.1 Hz); MS (EI) m/z (rel intensity) 236 [M]+ (54), 
218 (15), 128 (6), 127 (12), 110 (18), 109 (12), 63 (100), 55 (84); HRMS (EI) m/z calcd for 
C6H5IO2 235.9334, found 235.9338.  
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2-Iodo-1,3-phenylene-bis(trifluoromethanesulfonate) (112).112 A solution of 2-
iodoresorcinol (111) (5.90 g, 25.0 mmol) in dry CH2Cl2 (55.0 mL) was cooled to -78 oC 
with a dry-ice acetone bath and treated with DIPEA (10.4 mL, 60.0 mmol) via syringe 
pump over 5 min. Next triflic anhydride (8.5 mL, 50.0 mmol) was added via syringe 
pump over 15 min and stirring continued at -78 oC for ten min. The reaction mixture was 
warmed to 0 oC with an ice water bath over 1 h and then slowly quenched with water. 
The reaction mixture was extracted with CH2Cl2 and the combined organic extracts were 
washed with saturated aqueous sodium bicarbonate solution and brine, dried (Na2SO4), 
and concentrated in vacuo. The resultant oil was dissolved in 1:1 Ether/Hexanes (100 
mL) and silica gel (3.60 g) was added and stirred at rt for 30 min. The slurry was then 
filtered and the silica cake was washed with 1:1 Hex/Ether (200 mL). The resultant 
organic filtrate was concentrated in vacuo to give 12.1 g (24.2 mmol, 97%) of 112 as 
brown oil: 1H NMR (300 MHz, CDCl3) δ 7.57 (d, 1 H, J = 7.8 Hz), 7.54 (d, 1 H, J = 7.8 Hz), 
7.38 (d, 1 H, J = 8.4 Hz); MS (EI) m/z (rel intensity) 502 [M + 2]+ (13), 500 [M]+ (100), 493 
(10), 367 (90), 303 (25), 275 (15), 233 (9), 206 (12), 176 (9), 128 (7), 107 (35), 69 (25); HRMS 
(EI) m/z calcd for C8H3O6F6S2I 499.8320, found 499.8300.  
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3-(Benzyloxy)-2-iodophenyl-trifluoromethanesulfonate (108).107 To a 250 mL 
round-bottom flask with stir bar and reflux condenser was added compound 112 (12.0 g, 
24.0 mmol) and dissolved in 1,2-Dimethoxyethane (85.0 mL). To the reaction flask was 
added Cs2CO3 (9.52 g, 29.2 mmol) and heated to 80 oC for 4 h. The reaction mixture was 
cooled to room temperature and to it was added BnBr (3.50 mL, 29.0 mmol). The 
reaction was stirred for 5 h and then quenched with saturated aqueous NH4Cl solution 
and extracted with EtOAc. The combined organic extracts were washed with brine, dried 
(Na2SO4), and concentrated in vacuo. The resultant oil was purified via column 
chromatography on SiO2 (Rf  = 0.30, Hex/EtOAc, 4:1) to give 6.24 g (13.6 mmol, 57%) 
of 108 as amber/brown oil: 1H NMR (300 MHz, CDCl3) δ 7.55-7.31 (m, 6 H), 6.98 (d, 1 H, J 
= 8.1 Hz), 6.86 (d, 1 H, J = 8.1 Hz), 5.21 (s, 2 H); MS (EI) m/z (rel intensity) 459 [M + 1]+ (8), 
458 [M]+ (42), 367 (10), 309 (13), 218 (10), 198 (21), 107 (51), 91 (100), 79 (32), 69 (57), 65 
(75); HRMS (EI) m/z calcd for C14H10F3IO4S 457.9297, found 457.9316. 
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5-(Benzyloxy)-1,4-dimethoxynaphthaleneiodide (113). A solution of compound 108 
(1.0 g, 2.30 mmol) and 2-methoxyfuran (101) (0.257 mL, 2.70 mmol) in dry THF (2.25 mL) was 
cooled to -78 oC and treated with a 1.6 M solution of n-BuLi (1.27 mL, 2.03 mmol) dropwise 
over 15 min. After stirring for 10 min at -78 oC, the reaction mixture was quenched with water 
and extracted with ether. The ethereal extracts were combined, dried (MgSO4), and concentrated 
in vacuo. The resultant residue was chromatographed by flash column on SiO2 (Hex/EtOAc, 4:1) 
to give the cycloaddition product. Once concentrated, the resultant solid was dissolved in acetone 
(24.0 mL) and treated with potassium carbonate (3.10 g, 22.6 mmol) and dimethylsulfate (2.10 
mL, 22.6 mmol) and refluxed for 16 h. Once cool, the residual cesium carbonate salts were 
filtered out and the filtrate was concentrated in vacuo. The resultant residue was purified via 
flash chromatography on SiO2 (Rf  = 0.60 (1:1 Hex/EtOAc), Hex/EtOAc, 4:1) to give 0.485 g 
(1.65 mmol, 73%) of 113 as white solid: 1H NMR (300 MHz, CDCl3) δ 7.89 (d, 1 H, J = 8.4 Hz), 
7.60 (d, 1 H, J = 7.2 Hz), 7.43-7.32 (m, 3 H), 7.0 (d, 1 H, J = 7.5 Hz), 6.80 (d, 1 H, J = 8.4 Hz), 
6.74 (d, 1 H, J = 8.4 Hz), 5.21 (s, 2 H), 3.96 (s, 3 H), 3.89 (s, 3 H); MS (EI) m/z (rel intensity) 
295 [M + 1]+ (23), 294 [M]+ (97), 204 (13), 203 (67), 185 (10), 175 (17), 160 (25), 115 (39), 91 
(100), 65 (15), 55 (20); HRMS (EI) m/z calcd for C19H18O3 294.1256, found 294.1254. 
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5,8-Dimethoxynaphthalen-1-ol (115).111,113,114 A solution of compound 113 (0.485 g, 
1.60 mmol) in EtOAc (16.0 mL) was treated with 10.0 mol% Pd/C (0.177 g, 0.16 mmol) and 
stirred under H2 atmosphere (balloon) at rt. After stirring for 4.5 h, there was no change by TLC. 
A second 0.1 eq. of Pd/C was added (0.170 g, 0.164 mmol) and 1 drop of AcOH. The reaction 
was stirred under H2 atmosphere overnight. The reaction was filtered through celite and 
concentrated in vacuo. The resultant oil was purified by column chromatography on SiO2  (Rf = 
0.45 (1:1 Hex/EtOAc), Hex/EtOAc, 4:1) to give 0.230 g (1.13 mmol, 68%) of 115 as a white 
crystalline solid: Mp 98.1 – 102.0 oC (CH2Cl2); IR (ATR) (neat) 3332, 3090, 3017, 2965, 2943, 
1769, 1612, 1513, 1392, 1239, 1230, 1205, 1170, 1161, 1140, 1096, 1034 cm -1; 1H NMR (500 
MHz, CDCl3) δ 9.48 (s, 1 H), 7.73 (dd, 1 H, J = 5.1, 0.6 Hz), 7.39 (t, 1 H, J = 4.8 Hz), 6.94 (dd, 
1 H, J = 4.5, 0.6 Hz), 6.67 (dd, 1 H, J = 9.6, 5.1 Hz), 4.02 (s, 3 H), 3.96 (s, 3 H); 13C NMR (125 
MHz, CDCl3) δ 154.4, 150.3, 150.1, 128.4, 127.3, 115.6, 113.0, 111.4, 103.4, 103.0, 56.3, 55.8; 
MS (ES) m/z (rel intensity) 205 [M + 1]+ (10), 204 (58), 203 (28), 195 (70), 191 (13), 190 (40), 
189 (100), 175 (30), 174 (17), 159 (10), 119 (57); HRMS (ES) m/z calcd for C12H12O3 204.0786, 
found 204.0797. 
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1,4-Dimethoxy-5-(methoxymethoxy)naphthalene (89). A solution of compound 115 
(0.229 g, 1.15 mmol) in dry THF (11.5 mL) was cooled to 0 oC and treated with NaH (0.0540 g, 
1.35 mmol).  After stirring at 0 oC for 30 min, the reaction mixture was treated with MOMCl 
solution61 (0.450 mL, 1.57 mmol) and 5.0 mol % of TBAI (0.0140 g, 0.0563 mmol) and warmed 
to RT. After 2.5 h, the reaction mixture was quenched at 0 oC with saturated NH4Cl solution and 
extracted with ether. The organic extracts were combined, washed with brine, dried (MgSO4) and 
concentrated in vacuo. The crude reside was purified by column chromatography on SiO2, (Rf = 
0.8 (1:1 Hex/EtOAc), Hex/EtOAc, 9:1) to give 0.265 g (1.07 mmol, 95%) of 89 as a white solid: 
Mp 78.6 – 84.2 oC; IR (ATR) (neat) 3079, 3066, 2984, 2956, 2939, 2915, 1588, 1517, 1459, 
1411, 1383, 1368, 1277, 1247, 1236, 1208, 1169, 1155, 1114, 1075, 1042, 990,965, 943 cm -1; 
1H NMR (300 MHz, CDCl3) δ 7.98 (d, 1 H, J = 8.4 Hz), 7.39 (t, 1 H, J = 15.9, 7.8 Hz), 7.15 (d, 1 
H, J = 7.8), 6.80 (d, 1 H, J = 8.4 Hz), 6.73 (d, 1 H, J = 8.4 Hz), 5.26 (s, 2 H), 3.96 (s, 3 H), 3.92 
(s, 3 H), 3.62 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 153.6, 150.5, 149.7, 129.0, 125.8, 119.6, 
116.8, 114,8, 107.0, 104.0, 97.1, 57.3, 56.4, 55.8; MS (EI) m/z (rel intensity) 249 [M + 1]+ (15), 
248 [M]+ (100), 218 (20), 204 (19), 203 (55), 189 (22), 160 (22), 115 (48), 102 (18), 91 (73), 85 
(27), 81 (22), 71 (39), 69 (52), 57 (69), 55 (37); HRMS (EI) m/z calcd for C14H16O4 248.1049, 
found 248.1042.  
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